Inovio Pharmaceuticals (INO) 10-K 17 Mar 14 2013 FY Annual report Financial data

Document_and_Entity_Informatio

Document and Entity Information (USD $)	12 Months Ended
	Dec. 31, 2013	Mar. 07, 2014	Jun. 30, 2013
Document and Entity Information [Abstract]	'	'	'
Document Type	'10-K	'	'
Amendment Flag	'false	'	'
Document Period End Date	31-Dec-13	'	'
Document Fiscal Year Focus	'2013	'	'
Document Fiscal Period Focus	'FY	'	'
Entity Registrant Name	'INOVIO PHARMACEUTICALS, INC.	'	'
Entity Central Index Key	'0001055726	'	'
Current Fiscal Year End Date	'--12-31	'	'
Entity Filer Category	'Accelerated Filer	'	'
Entity Common Stock, Shares Outstanding	'	239,609,760	'
Entity Well-known Seasoned Issuer	'No	'	'
Entity Public Float	'	'	$133,199,615
Entity Current Reporting Status	'Yes	'	'
Entity Voluntary Filers	'No	'	'

Consolidated_Balance_Sheets

Consolidated Balance Sheets (USD $)	Dec. 31, 2013		Dec. 31, 2012
Current assets:	'		'
Cash and cash equivalents	$33,719,796		$5,646,021
Short-term investments	18,905,608		8,034,001
Accounts receivable	3,301,563		830,433
Accounts receivable from affiliated entity	0		36,234
Prepaid expenses and other current assets	637,433		471,328
Prepaid expenses and other current assets from affiliated entity	2,057,350		887,167
Deferred tax asset	61,839		62,728
Total current assets	58,683,589		15,967,912
Restricted cash	100,762		100,410
Fixed assets, net	2,886,545		363,021
Investment in affiliated entity	9,664,587		10,703,332
Intangible assets, net	5,718,778		7,489,315
Goodwill	10,113,371	[1]	10,113,371	[1]
Common stock warrants	717,500		267,200
Other assets	402,075		134,193
Total assets	88,287,207		45,138,754
Current liabilities:	'		'
Accounts payable and accrued expenses	5,444,508		3,181,574
Accounts payable and accrued expenses due to affiliated entity	522,255		187,275
Accrued clinical trial expenses	1,446,180		1,405,896
Common stock warrants	19,540,583		2,859,899
Deferred revenue	1,624,388		353,391
Deferred revenue from affiliated entity	388,542		388,542
Total current liabilities	28,966,456		8,376,577
Deferred revenue, net of current portion	1,997,333		88,609
Deferred revenue from affiliated entity, net of current portion	1,211,694		1,586,694
Deferred rent	3,013,263		65,076
Deferred tax liabilities	195,778		164,393
Total liabilities	35,384,524		10,281,349
Commitments and contingencies	'		'
Inovio Pharmaceuticals, Inc. stockholders’ equity:	'		'
Preferred stock—par value $0.001; Authorized shares: 10,000,000, issued and outstanding shares: 26 at both December 31, 2013 and December 31, 2012	0		0
Common stock—par value $0.001; Authorized shares: 600,000,000 at December 31, 2013 and 300,000,000 at December 31, 2012, issued and outstanding: 210,304,821 at December 31, 2013 and 144,313,005 at December 31, 2012	210,305		144,313
Additional paid-in capital	348,109,661		263,897,116
Accumulated deficit	-295,788,577		-229,760,129
Accumulated other comprehensive (loss) income	-76,365		73,362
Total Inovio Pharmaceuticals, Inc. stockholders’ equity	52,455,024		34,354,662
Non-controlling interest	447,659		502,743
Total stockholders' equity	52,902,683		34,857,405
Total liabilities and stockholders’ equity	$88,287,207		$45,138,754
[1]	Goodwill was recorded from the Inovio AS acquisition in January 2005 and from the acquisition of VGX in June 2009 for $3.9 million and $6.2 million, respectively.

Consolidated_Balance_Sheets_Pa

Consolidated Balance Sheets Parenthetical (USD $)	Dec. 31, 2013	Dec. 31, 2012
Statement of Financial Position [Abstract]	'	'
Preferred stock, par value (Dollars per share)	$0.00	$0.00
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred stock, shares issued	26	26
Preferred stock, shares outstanding	26	26
Common stock, par value (Dollars per share)	$0.00	$0.00
Common stock, shares authorized	600,000,000	300,000,000
Common stock, shares issued	210,304,821	144,313,005
Common stock, shares outstanding	210,304,821	144,313,005

Consolidated_Statements_of_Ope

Consolidated Statements of Operations (Unaudited) (USD $)	3 Months Ended								12 Months Ended
	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2012	Sep. 30, 2012	Jun. 30, 2012	Mar. 31, 2012	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Revenues:	'	'	'	'	'	'	'	'	'	'	'
Revenue under collaborative research and development arrangements	$822,217	$8,388,760	$14,311	$14,259	$14,296	$22,495	$20,907	$24,838	$9,239,547	$82,536	$156,397
Revenue under collaborative research and development arrangements with affiliated entity	106,250	106,250	106,250	106,250	142,483	222,484	106,250	106,250	425,000	577,467	411,459
Grants and miscellaneous revenue	811,199	991,835	665,049	1,334,716	977,974	609,717	308,925	1,562,033	3,802,799	3,458,649	9,227,401
Total revenues	1,739,666	9,486,845	785,610	1,455,225	1,134,753	854,696	436,082	1,693,121	13,467,346	4,118,652	9,795,257
Operating expenses:	'	'	'	'	'	'	'	'	'	'	'
Research and development	6,404,005	5,438,405	4,411,082	5,115,112	4,442,841	4,972,319	4,527,086	4,042,579	21,368,604	17,984,825	20,032,001
General and administrative	4,339,539	3,282,796	3,046,586	2,974,153	2,919,000	2,674,362	2,696,909	2,488,088	13,643,074	10,778,359	11,988,796
Gain on sale of intangible assets	-1,000,000	0	-1,000,000	0	0	-500,000	0	-651,000	-2,000,000	-1,151,000	-587,000
Total operating expenses	9,743,544	8,721,201	6,457,668	8,089,265	7,361,841	7,146,681	7,223,995	5,879,667	33,011,678	27,612,184	31,433,797
Loss from operations	-8,003,878	765,644	-5,672,058	-6,634,040	-6,227,088	-6,291,985	-6,787,913	-4,186,546	-19,544,332	-23,493,532	-21,638,540
Other income (expense):	'	'	'	'	'	'	'	'	'	'	'
Interest and other income, net	8,576	46,787	37,391	39,460	56,520	37,013	41,036	31,544	132,214	166,113	34,285
Change in fair value of common stock warrants	-6,052,965	-34,952,210	-3,199,878	-1,427,616	3,049,649	-1,113,638	3,594,782	-3,548,173	-45,632,669	1,982,620	8,690,658
(Loss) Gain on investment in affiliated entity	-1,419,536	3,248,926	-2,032,051	-836,084	2,449,615	736,121	-992,373	-561,544	-1,038,745	1,631,819	-2,390,498
Net loss	-15,467,803	-30,890,853	-10,866,596	-8,858,280	-671,304	-6,632,489	-4,144,468	-8,264,719	-66,083,532	-19,712,980	-15,304,095
Net loss attributable to non-controlling interest	13,473	13,443	14,008	14,160	12,553	10,413	11,289	9,770	55,084	44,025	51,150
Net loss attributable to Inovio Pharmaceuticals, Inc.	($15,454,330)	($30,877,410)	($10,852,588)	($8,844,120)	($658,751)	($6,622,076)	($4,133,179)	($8,254,949)	($66,028,448)	($19,668,955)	($15,252,945)
Loss per common share—basic and diluted:	'	'	'	'	'	'	'	'	'	'	'
Net loss per share attributable to Inovio Pharmaceuticals, Inc. stockholders (In dollars per share)	($0.07)	($0.16)	($0.06)	($0.06)	$0	($0.05)	($0.03)	($0.06)	($0.36)	($0.14)	($0.12)
Weighted average number of common shares outstanding—basic and diluted (In shares)	208,509,676	191,956,155	179,954,816	156,155,532	140,704,889	135,389,308	134,968,394	134,968,394	184,351,090	136,509,247	126,239,336

Consolidated_Statements_of_Com

Consolidated Statements of Comprehensive Loss (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Statement of Comprehensive Income [Abstract]	'	'	'
Net loss	($66,083,532)	($19,712,980)	($15,304,095)
Other comprehensive income (loss):	'	'	'
Foreign currency translation adjustments	118	1,984	-3,263
Unrealized (loss) gain on short-term investments	-149,845	35,985	35,806
Comprehensive loss	-66,233,259	-19,675,011	-15,271,552
Comprehensive loss attributable to non-controlling interest	55,084	44,025	51,150
Comprehensive loss attributable to Inovio Pharmaceuticals, Inc.	($66,178,175)	($19,630,986)	($15,220,402)

Consolidated_Statements_of_Sto

Consolidated Statements of Stockholders' Equity (USD $)

Total

Preferred Stock [Member]

Common Stock [Member]

Additional Paid-in Capital [Member]

Accumulated Deficit [Member]

Accumulated Other Comprehensive Income (Loss) [Member]

Noncontrolling Interest [Member]

Warrants For Cash [Member]

Warrants For Cash [Member]

Warrants For Cash [Member]

Equity Financing [Member]

Equity Financing [Member]

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

Common Stock [Member]

Additional Paid-in Capital [Member]

USD ($)

Additional Paid-in Capital [Member]

USD ($)

USD ($)

USD ($)

Beginning balance, value at Dec. 31, 2010

$47,100,911

'

$105,038

$241,233,334

($194,838,229)

$2,850

$597,918

'

'

'

'

'

Beginning balance, shares at Dec. 31, 2010

'

26

105,038,192

'

'

'

'

'

'

'

'

'

Increase (Decrease) in Stockholders' Equity [Roll Forward]

'

'

'

'

'

'

'

'

'

'

'

'

Issuance of common stock for cash, net of financing costs, shares

'

'

1,028,905

'

'

'

'

'

'

'

'

'

Issuance of common stock for cash, net of financing costs, value

1,351,669

'

1,029

1,350,640

'

'

'

'

'

'

'

'

Issuance of common stock and warrants for cash, net of financing costs, shares

'

'

21,130,400

'

'

'

'

'

7,699,712

'

'

'

Issuance of common stock and warrants for cash, net of financing costs, value

22,957,803

'

21,130

22,936,673

'

'

'

3,685,129

7,700

3,677,429

'

'

Fair value of common stock warrants issued in connection with equity financing

-11,727,372

'

'

-11,727,372

'

'

'

'

'

'

-1,905,679

-1,905,679

Exercise of stock options and warrants for cash, shares

'

'

71,185

'

'

'

'

'

'

'

'

'

Exercise of stock options and warrants for cash, value

15,930

'

71

15,859

'

'

'

'

'

'

'

'

Stock-based compensation

1,654,823

'

'

1,654,823

'

'

'

'

'

'

'

'

Net loss attributable to common stockholders

-15,304,095

'

'

'

-15,252,945

'

-51,150

'

'

'

'

'

Unrealized gain (loss) on short-term investments

35,806

'

'

'

'

35,806

'

'

'

'

'

'

Foreign currency translation adjustments

-3,263

'

'

'

'

-3,263

'

'

'

'

'

'

Ending balance, value at Dec. 31, 2011

47,861,662

'

134,968

257,235,707

-210,091,174

35,393

546,768

'

'

'

'

'

Ending balance, shares at Dec. 31, 2011

'

26

134,968,394

'

'

'

'

'

'

'

'

'

Increase (Decrease) in Stockholders' Equity [Roll Forward]

'

'

'

'

'

'

'

'

'

'

'

'

Issuance of common stock for cash, net of financing costs, shares

'

'

9,344,611

'

'

'

'

'

'

'

'

'

Issuance of common stock for cash, net of financing costs, value

5,325,141

'

9,345

5,315,796

'

'

'

'

'

'

'

'

Stock-based compensation

1,345,613

'

'

1,345,613

'

'

'

'

'

'

'

'

Net loss attributable to common stockholders

-19,712,980

'

'

'

-19,668,955

'

-44,025

'

'

'

'

'

Unrealized gain (loss) on short-term investments

35,985

'

'

'

'

35,985

'

'

'

'

'

'

Foreign currency translation adjustments

1,984

'

'

'

'

1,984

'

'

'

'

'

'

Ending balance, value at Dec. 31, 2012

34,857,405

'

144,313

263,897,116

-229,760,129

73,362

502,743

'

'

'

'

'

Ending balance, shares at Dec. 31, 2012

'

26

144,313,005

'

'

'

'

'

'

'

'

'

Increase (Decrease) in Stockholders' Equity [Roll Forward]

'

'

'

'

'

'

'

'

'

'

'

'

Issuance of common stock for cash, net of financing costs, shares

'

'

15,700,668

'

'

'

'

'

'

'

'

'

Issuance of common stock for cash, net of financing costs, value

18,924,856

'

15,701

18,909,155

'

'

'

'

'

'

'

'

Issuance of common stock and warrants for cash, net of financing costs, shares

'

'

27,377,266

'

'

'

'

'

'

'

'

'

Issuance of common stock and warrants for cash, net of financing costs, value

14,274,819

'

27,377

14,247,442

'

'

'

'

'

'

'

'

Fair value of common stock warrants issued in connection with equity financing

-5,968,244

'

'

-5,968,244

'

'

'

'

'

'

'

'

Exercise of stock options and warrants for cash, shares

'

'

22,849,755

'

'

'

'

'

'

'

'

'

Exercise of stock options and warrants for cash, value

19,808,232

'

22,850

19,785,382

'

'

'

'

'

'

'

'

Cashless exercise of warrants, shares

'

'

64,127

'

'

'

'

'

'

'

'

'

Cashless exercise of warrants, value

0

'

64

-64

'

'

'

'

'

'

'

'

Change in classification of warrants from liability to equity due to exercise

35,370,529

'

'

35,370,529

'

'

'

'

'

'

'

'

Stock-based compensation

1,868,345

'

'

1,868,345

'

'

'

'

'

'

'

'

Net loss attributable to common stockholders

-66,083,532

'

'

'

-66,028,448

'

-55,084

'

'

'

'

'

Unrealized gain (loss) on short-term investments

-149,845

'

'

'

'

-149,845

'

'

'

'

'

'

Foreign currency translation adjustments

118

'

'

'

'

118

'

'

'

'

'

'

Ending balance, value at Dec. 31, 2013

$52,902,683

'

$210,305

$348,109,661

($295,788,577)

($76,365)

$447,659

'

'

'

'

'

Ending balance, shares at Dec. 31, 2013

'

26

210,304,821

'

'

'

'

'

'

'

'

'

Consolidated_Statements_of_Sto1

Consolidated Statements of Stockholders' Equity (Parenthetical) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Issuance of common stock for cash, financing costs	$585,000	$164,695	$41,838
Issuance of common stock and warrants for cash, financing costs	783,000	'	1,300,000
Warrants For Cash [Member]	'	'	'
Issuance of common stock and warrants for cash, financing costs	'	'	$314,871

Consolidated_Statements_of_Cas

Consolidated Statements of Cash Flows (Unaudited) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Cash flows from operating activities:	'	'	'
Net loss	($66,083,532)	($19,712,980)	($15,304,095)
Adjustments to reconcile net loss to net cash used in operating activities:	'	'	'
Depreciation	328,752	173,750	142,197
Amortization of intangible assets	1,770,537	1,821,170	1,869,517
Change in value of common stock warrants	45,632,669	-1,982,620	-8,690,658
Stock-based compensation	1,868,345	1,345,613	1,654,823
Interest income accrued on short-term investments	-484	-1,147	6,271
Deferred taxes	32,274	22,806	25,673
Deferred rent	410,187	-15,799	13,763
Transaction costs associated with issuance of warrants	315,970	0	0
Loss on short-term investments	38,950	0	0
Loss on disposal of fixed assets	1,822	0	0
Loss (Gain) on investment in affiliated entity	1,038,745	-1,631,819	2,390,498
Gain on sale of intangible assets	-2,000,000	-1,151,000	-587,000
Changes in operating assets and liabilities:	'	'	'
Accounts receivable	-2,471,130	-362,524	-435,022
Accounts receivable from affiliated entity	36,234	2,172	33,743
Prepaid expenses and other current assets	-229,705	363,584	-472,074
Prepaid expenses and other current assets from affiliated entity	-1,401,258	-445,981	212,250
Restricted cash	-352	-351	-100,059
Other assets	26,793	-14,794	50,866
Accounts payable and accrued expenses	2,164,045	-790,844	1,789,376
Accounts payable and accrued expenses due to affiliated entity	334,980	166,931	-1,660,603
Deferred revenue	3,179,721	282,048	-333,725
Deferred revenue from affiliated entity	-375,000	-375,000	-361,458
Net cash used in operating activities	-15,381,437	-22,306,785	-19,755,717
Cash flows from investing activities:	'	'	'
Purchases of investments	-15,399,495	-9,142,220	-18,193,614
Maturities of investments	4,339,577	14,008,771	7,206,000
Purchases of capital assets	-176,925	-240,986	-161,187
Additional investment in affiliated entity	0	0	-101,123
Proceeds from sale of intangible assets	2,000,000	650,000	350,000
Net cash (used in) provided by investing activities	-9,236,843	5,275,565	-10,899,924
Cash flows from financing activities:	'	'	'
Proceeds from issuance of common stock and warrants, net of issuance costs	32,883,705	5,325,141	27,994,601
Proceeds from stock option and warrant exercises	19,808,232	0	15,930
Net cash provided by financing activities	52,691,937	5,325,141	28,010,531
Effect of exchange rate changes on cash and cash equivalents	118	1,984	-3,263
Increase (Decrease) in cash and cash equivalents	28,073,775	-11,704,095	-2,648,373
Cash and cash equivalents, beginning of period	5,646,021	17,350,116	19,998,489
Cash and cash equivalents, end of period	33,719,796	5,646,021	17,350,116
Supplemental disclosure of non-cash activities	'	'	'
Lease incentive	$2,538,000	$0	$0

The_Company

The Company	12 Months Ended
	Dec. 31, 2013
Organization, Consolidation and Presentation of Financial Statements [Abstract]	'
The Company	'
	The Company
	Inovio Pharmaceuticals, Inc. (the “Company” or “Inovio”) is developing vaccines and immune therapies, called synthetic vaccines, focused on cancers and infectious diseases. The Company's DNA-based immune therapies, in combination with its proprietary electroporation delivery devices, are generating immune responses, with therapeutic T-cell responses exceeding other technologies in terms of magnitude, breadth, and response rate. In addition, the Company's novel SynCon® vaccine design has shown the ability to help break the immune system’s tolerance of cancerous cells. Given the recognized role of killer T cells in eliminating cancerous or infected cells from the body, Inovio’s scientists believe that its active immunotherapies may play an important role in helping fight these diseases. Inovio's SynCon® design is also intended to provide universal protection against known as well as new unmatched strains of pathogens such as influenza. Human data to date have shown a favorable safety profile of the Company's DNA vaccines delivered using electroporation. The Company has completed, current or planned clinical programs of its proprietary SynCon® vaccines and immunotherapies for HPV-caused pre-cancers and cancers (therapeutic), influenza (preventive), prostate cancer (therapeutic), breast/lung/pancreatic cancer (therapeutic), hepatitis C virus (HCV) (therapeutic), hepatitis B virus (HBV) (therapeutic), HIV, and malaria (preventive and therapeutic). The Company's partners and collaborators include Roche, University of Pennsylvania, Drexel University, National Microbiology Laboratory of the Public Health Agency of Canada, Program for Appropriate Technology in Health/Malaria Vaccine Initiative (“PATH”/ “MVI”), National Institute of Allergy and Infectious Diseases (“NIAID”), Merck, United States Military HIV Research Program (“USMHRP”), U.S. Army Medical Research Institute of Infectious Diseases (“USAMRIID”), HIV Vaccines Trial Network (“HVTN”) and Department of Homeland Security (“DHS”).

Summary_of_Significant_Account

Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2013
Accounting Policies [Abstract]	'
Summary of Significant Accounting Policies	'
	Summary of Significant Accounting Policies
	Basis of Presentation
	Inovio incurred a net loss of $66.0 million for the year ended December 31, 2013. Inovio had working capital of $29.7 million and an accumulated deficit of $295.8 million as of December 31, 2013. The Company’s ability to continue its operations is dependent upon its ability to obtain additional capital in the future and achieve profitable operations. The Company expects to continue to rely on outside sources of financing to meet its capital needs and the Company may never achieve positive cash flow. These consolidated financial statements do not include any adjustments to the specific amounts and classifications of assets and liabilities, which might be necessary should Inovio be unable to continue in business. Inovio’s consolidated financial statements as of and for the year ended December 31, 2013 have been prepared on a going concern basis, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business for the foreseeable future. The Company has evaluated subsequent events after the balance sheet date through the date it issued these financial statements.
	Reclassification
	Certain reclassifications have been made to the prior year consolidated financial statements to conform to the current year presentation.
	Consolidation
	These consolidated financial statements include the accounts of Inovio Pharmaceuticals, Inc. and its subsidiaries. In conjunction with the acquisition in June 2009 of VGX Pharmaceuticals (the “Merger”), the Company acquired an 88% interest in VGX Animal Health and certain shares in VGX International, Inc. (“VGX Int'l”) (a publicly-traded company in South Korea). The Company consolidates Genetronics, Inc., VGX Pharmaceuticals and its subsidiary VGX Animal Health and records a non-controlling interest for the 9% of VGX Animal Health it does not own as of December 31, 2013 and 2012. The Company's investment in VGX Int'l, which is recorded as investment in affiliated entity within the consolidated balance sheets is accounted for at fair value on a recurring basis, with changes in fair value recorded on the consolidated statements of operations within gain (loss) on investment in affiliated entity. All intercompany accounts and transactions have been eliminated upon consolidation.
	Variable Interest Entities
	In June 2009, the FASB issued authoritative guidance that requires companies to perform a qualitative analysis to determine whether a variable interest in another entity represents a controlling financial interest in a variable interest entity. A controlling financial interest in a variable interest entity is characterized by having both the power to direct the most significant activities of the entity and the obligation to absorb losses or the right to receive benefits of the entity. This guidance also requires on-going reassessments of variable interests based on changes in facts and circumstances. This guidance became effective for fiscal years beginning after November 15, 2009. The Company adopted the provisions of the guidance in the first quarter of 2010 and determined that none of the entities with which the Company currently conducts business and collaborations are variable interest entities, except VGXI (a wholly-owned subsidiary of VGX Int'l). The Company determined that they are not the primary beneficiary and therefore are not required to consolidate VGXI. The Company continues to assess its variable interests and has determined that no significant changes have occurred as of December 31, 2013.
	Use of Estimates
	The preparation of consolidated financial statements in accordance with United States generally accepted accounting principles requires the Company to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. Inovio bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions. On an ongoing basis, the Company reviews its estimates to ensure that these estimates appropriately reflect changes in the business or as new information becomes available.
	Concentration of Credit Risk
	Financial instruments, which potentially subject the Company to concentrations of credit risk, consist primarily of cash and cash equivalents, and short-term investments. The Company limits its exposure to credit loss by placing its cash and investments with high credit quality financial institutions. Additionally, the Company has established guidelines regarding diversification of its investments and their maturities which are designed to maintain principal and maximize liquidity. The Company had contracts with customers which represented more than 10% of total revenues for all of the years presented as discussed in Note 6.
	Fair value of Financial Instruments
	The Company’s financial instruments consist principally of cash equivalents, short-term investments, investment in affiliated entity and common stock warrants. The carrying amounts of cash equivalents approximate the related fair values due to the short-term maturities of these instruments. Investments consist of available-for-sale securities that are reported at fair value with the related unrealized gains and losses included in accumulated other comprehensive loss, a component of consolidated stockholders’ equity. The Company’s investment in affiliated entity is accounted for at fair value on a recurring basis, with changes in fair value recorded on the consolidated statements of operations within gain(loss) from investment in affiliated entity. The estimated fair value of the common stock warrants is determined by using the Black-Scholes pricing model as of December 31, 2013, as discussed in Note 5.
	Cash and Cash Equivalents
	Cash equivalents are considered by the Company to be highly liquid investments purchased with original maturities of three months or less from the date of purchase. Cash and cash equivalents include certain money market accounts at December 31, 2013 and 2012.
	Restricted Cash
	Restricted cash consists of a certificate of deposit with a term of 90 days which has been pledged as collateral with a financial institution. The certificate of deposit has been classified as held-to-maturity and is accounted for at amortized cost which approximates fair value. The certificate of deposit and accrued interest will automatically renew at each maturity date until termination of the agreement.
	Investments
	The Company defines investments as income yielding securities that can be readily converted into cash. Investments include mutual funds and municipal bonds at December 31, 2013 and certificates of deposit, mutual funds, and municipal bonds at December 31, 2012.
	Accounts Receivable
	Accounts receivable are recorded at invoiced amounts and do not bear interest. Inovio performs ongoing credit evaluations of our customers’ financial condition. Credit is extended to customers as deemed necessary and generally does not require collateral. Management believes that the risk of loss is significantly reduced due to the quality and financial position of our customers. No allowance for doubtful accounts was deemed necessary at December 31, 2013 and 2012.
	Fixed Assets
	Property and equipment are stated at cost and depreciated using the straight-line method over the estimated useful life of the assets, generally three to five years. Leasehold improvements are amortized over the shorter of the remaining term of the related leases or the estimated economic useful lives of the improvements. Repairs and maintenance are expensed as incurred.
	Long-Lived Assets
	All long-lived assets are reviewed for impairment in value when changes in circumstances dictate, based upon undiscounted future operating cash flows, and appropriate losses are recognized and reflected in current earnings, to the extent the carrying amount of an asset exceeds its estimated fair value determined by the use of appraisals, discounted cash flow analyses or comparable fair values of similar assets. The Company has not recognized any losses on long-lived assets through December 31, 2013.
	Valuation of Goodwill and Intangible Assets
	Goodwill represents the excess of acquisition cost over the fair value of the net assets of acquired businesses. Intangible assets are amortized over their estimated useful lives ranging from 5 to 18 years. Acquired intangible assets are continuously being developed for the future economic viability contemplated at the time of acquisition. The Company is concurrently conducting pre-clinical, Phase I, and Phase II trials using the acquired intangibles, and has entered into certain significant licensing agreements for use of these acquired intangibles.
	Historically the Company has recorded patents at cost and amortized these costs using the straight-line method over the expected useful lives of the patents or 17 years, whichever is less. Patent cost consists of the consideration paid for patents and related legal costs. Effective June 1, 2009, in connection with the acquisition of VGX, all new patent costs are being expensed as incurred. Patent cost capitalized as of June 1, 2009 will continue to be amortized over the expected life of the patent. License costs are recorded based on the fair value of consideration paid and amortized using the straight-line method over the shorter of the expected useful life of the underlying patents or the term of the related license agreement to the extent the license has an alternative future use. As of December 31, 2013 and 2012, the Company’s intangible assets resulting from the acquisition of VGX and Inovio AS, and additional intangibles including previously capitalized patent costs and license costs, net of accumulated amortization, totaled $5.7 million and $7.5 million, respectively.
	The determination of the value of such intangible assets requires management to make estimates and assumptions that affect the Company’s consolidated financial statements. The Company assesses potential impairments to intangible assets when there is evidence that events or changes in circumstances indicate that the carrying amount of an asset may not be recovered. The Company’s judgments regarding the existence of impairment indicators and future cash flows related to intangible assets are based on operational performance of our acquired businesses, market conditions and other factors. If impairment is indicated, the Company will reduce the carrying value of the intangible asset to fair value. While current and historical operating and cash flow losses are potential indicators of impairment, the Company believes the future cash flows to be received from its intangible assets will exceed the intangible assets’ carrying value, and accordingly, the Company has not recognized any impairment losses through December 31, 2013.
	Goodwill is not amortized but instead is measured for impairment annually, or when events indicate that impairment exists. The Company’s accounting policy with respect to reviewing goodwill for impairment is a two step process. The first step of the impairment test compares the fair value of our reporting unit with its carrying value including allocated goodwill. If the carrying value of the Company’s reporting unit exceeds its fair value, then the second step of the impairment test is performed to measure the impairment loss, if any. The Company tests goodwill for impairment at the entity level, which is considered our reporting unit. The Company’s estimate of fair value is determined using both the Discounted Cash Flow method of the Income Approach and the Guideline Public Company method of the Market Approach. The Discounted Cash Flow method estimates future cash flows of our business for a certain discrete period and then discounts them to their present value. The Guideline Public Company method computes value indicators (“multiples”) from the operating data of the selected publicly traded guideline companies. After these multiples were evaluated, appropriate value indicators were selected and applied to the operating statistics of the reporting unit to arrive at indications of value. Specifically, the Company relied upon the application of Total Invested Capital based valuation multiples for each guideline company. In applying the Income and Market Approaches, premiums and discounts were determined and applied to estimate the fair values of the reporting unit. To arrive at the indicated value of equity under each approach, the Company then assigned a relative weighting to the resulting values from each approach to determine whether the carrying value of the reporting unit exceeds its fair value, thus requiring step two of the impairment test.
	The Company conducts the impairment test annually on November 30th for each fiscal year for which goodwill is evaluated for impairment. The Company is also aware of the requirement to evaluate goodwill for impairment at other times should circumstances arise. To date, the Company has concluded that the fair value of the reporting unit exceeded the carrying value and therefore, step two of the impairment test has never been performed.
	Although there are inherent uncertainties in this assessment process, the estimates and assumptions the Company is using are consistent with its internal planning. If these estimates or their related assumptions change in the future, the Company may be required to record an impairment charge on all or a portion of our goodwill and intangible assets. Furthermore, the Company cannot predict the occurrence of future impairment triggering events nor the impact such events might have on its reported asset values. Future events could cause the Company to conclude that impairment indicators exist and that goodwill or other intangible assets associated with its acquired businesses are impaired. Any resulting impairment loss could have an adverse impact on the Company’s results of operations. See Note 8 for further discussion of the Company’s goodwill and intangible assets.
	Income Taxes
	The Company recognizes deferred tax assets and liabilities for temporary differences between the financial reporting basis and the tax basis of the Company’s assets and liabilities along with net operating loss and tax credit carry forwards. The Company records a valuation allowance against its deferred tax assets to reduce the net carrying value to an amount that it believes is more likely than not to be realized. When the Company establishes or reduces the valuation allowance against its deferred tax assets, its provision for income taxes will increase or decrease, respectively, in the period such determination is made.
	Valuation allowances against the Company’s deferred tax assets were $61.1 million and $52.2 million at December 31, 2013 and 2012, respectively. Changes in the valuation allowances, when they are recognized in the provision for income taxes, are included as a component of the estimated annual effective tax rate.
	Revenue Recognition
	Grant revenue
	Inovio receives non-refundable grants under available government programs. Government grants towards current expenditures are recorded as revenue when there is reasonable assurance that we have complied with all conditions necessary to receive the grants, collectability is reasonably assured, and as the expenditures are incurred.
	License fee and milestone revenue
	Inovio has adopted a strategy of co-developing or licensing its gene delivery technology for specific genes or specific medical indications. Accordingly, the Company has entered into collaborative research and development agreements and has received funding for pre-clinical research and clinical trials. Prior to the adoption of the Financial Accounting Standards Board's (“FASB”) Accounting Standards Update (“ASU”) No. 2009-13, Revenue Recognition (Topic 605): Multiple-Deliverable Revenue Arrangements, the Company analyzed its multiple element arrangements to determine whether the identified deliverables could be accounted for individually as separate units of accounting. The delivered item(s) were considered a separate unit of accounting if all of the following criteria were met: (1)the delivered item(s) has value to the customer on a standalone basis; (2)there is objective and reliable evidence of the fair value of the undelivered item(s); and (3) if the arrangement includes a general right of return relative to the delivered item, delivery or performance of the undelivered item(s) is considered probable and substantially in our control. If these criteria were not met, the deliverable was combined with other deliverables in the arrangement and accounted for as a combined unit of accounting.
	For new collaborative agreements or material modifications of existing collaborative agreements entered into after December 31, 2010, Inovio follows the provisions of ASU No. 2009-13. In order to account for the multiple-element arrangements, the Company identifies the deliverables included within the agreement and evaluates which deliverables represent separable units of accounting. Analyzing the arrangement to identify deliverables requires the use of judgment, and each deliverable may be an obligation to deliver services, a right or license to use an asset, or another performance obligation. A delivered item is considered a separate unit of accounting when the delivered item has value to the collaborator on a standalone basis based on the consideration of the relevant facts and circumstances for each arrangement.
	Arrangement consideration is allocated at the inception of the agreement to all identified units of accounting based on their relative selling price. The relative selling price for each deliverable is determined using vendor specific objective evidence (“VSOE”), of selling price or third-party evidence of selling price if VSOE does not exist. If neither VSOE nor third-party evidence of selling price exists, we use our best estimate of the selling price for the deliverable. The amount of allocable arrangement consideration is limited to amounts that are fixed or determinable. The consideration received is allocated among the separate units of accounting, and the applicable revenue recognition criteria are applied to each of the separate units. Changes in the allocation of the sales price between delivered and undelivered elements can impact revenue recognition but do not change the total revenue recognized under any agreement.
	Upfront license fee payments are recognized upon delivery of the license if facts and circumstances dictate that the license has standalone value from the undelivered items, the relative selling price allocation of the license is equal to or exceeds the upfront license fee, persuasive evidence of an arrangement exists, our price to the collaborator is fixed or determinable, and collectability is reasonably assured. Upfront license fee payments are deferred if facts and circumstances dictate that the license does not have standalone value. The determination of the length of the period over which to defer revenue is subject to judgment and estimation and can have an impact on the amount of revenue recognized in a given period.
	Prior to the adoption of ASU No. 2010-17, Revenue Recognition (Topic 605): Milestone Method of Revenue Recognition (“Milestone Method”), Inovio recognized non-refundable milestone payments upon the achievement of specified milestones upon which we had earned the milestone payment, provided the milestone payment was substantive in nature and the achievement of the milestone was not reasonably assured at the inception of the agreement. The Company deferred payments for milestone events that were reasonably assured and recognized them ratably over the minimum remaining period of our performance obligations. Payments for milestones that were not reasonably assured were treated as the culmination of a separate earnings process and were recognized as revenue when the milestones were achieved.
	Effective January 1, 2011, the Company adopted on a prospective basis the Milestone Method of ASU No. 2010-17. Under the Milestone Method, the Company will recognize consideration that is contingent upon the achievement of a milestone in its entirety as revenue in the period in which the milestone is achieved only if the milestone is substantive in its entirety. A milestone is considered substantive when it meets all of the following criteria:
	1	The consideration is commensurate with either the entity's performance to achieve the milestone or the enhancement of the value of the delivered item(s) as a result of a specific outcome resulting from the entity's performance to achieve the milestone,
	2	The consideration relates solely to past performance, and
	3	The consideration is reasonable relative to all of the deliverables and payment terms within the arrangement.
	A milestone is defined as an event (i) that can only be achieved based in whole or in part on either the entity's performance or on the occurrence of a specific outcome resulting from the entity's performance, (ii) for which there is substantive uncertainty at the date the arrangement is entered into that the event will be achieved and (iii) that would result in additional payments being due to the Company.
	Research and Development Expenses
	Since Inovio’s inception, virtually all of the Company’s activities have consisted of research and development efforts related to developing electroporation technologies and DNA vaccines. Research and development expenses consist of expenses incurred in performing research and development activities including salaries and benefits, facilities and other overhead expenses, clinical trials, contract services and other outside expenses. Research and development expenses are charged to operations as they are incurred.
	Net Loss Per Share
	Basic net loss per share is computed by dividing the net loss for the year by the weighted average number of common shares outstanding during the year. Diluted loss per share is calculated in accordance with the treasury stock method and reflects the potential dilution that would occur if securities or other contracts to issue common stock were exercised or converted to common stock. Since the effect of the assumed exercise of common stock options, warrants and other convertible securities was anti-dilutive for all periods presented, basic and diluted loss per share are the same.
	The following table summarizes potential common shares that were excluded from diluted net loss per share calculation because of their anti-dilutive effect:
		Year Ended December 31,
		2013		2012		2011
	Options to purchase common stock	16,538,118		16,257,444		14,302,803
	Warrants to purchase common stock	14,059,260		21,593,844		21,743,844
	Convertible preferred stock	38,233		38,233		38,233
	Total	30,635,611		37,889,521		36,084,880
	Leases
Leases are classified as either capital or operating leases. Leases which transfer substantially all of the benefits and risks incidental to the ownership of assets are accounted for as if there was an acquisition of an asset and incurrence of an obligation at the inception of the lease. All other leases are accounted for as operating leases. Inovio’s Blue Bell, PA headquarters and San Diego, CA facility leases, which have escalating payments, are both expensed on a straight-line basis over the term of the lease. The allowance provided by the lessor for leasehold improvements are considered tenant incentives and are amortized on a straight-line basis over the term of the lease. These leases represent the primary expense and commitment as indicated in Note 11 “Commitments” below. Other leases exist for office machinery, such as copiers, wherein lease expense is recorded as incurred.
Stock-Based Compensation
The Company recognizes compensation expense for all share-based awards made to employees, directors, and non-employees. Inovio estimates the fair value of stock options granted using the Black-Scholes option pricing model. The Black-Scholes option pricing model was developed for use in estimating the fair value of traded options, which have no vesting restrictions and are fully transferable. In addition, option valuation models require the input of highly subjective assumptions, including the expected stock price volatility and expected option life. Inovio measures the fair value of employee and director awards at the date of grant. For non-employee awards, Inovio measures the fair value at each reporting period. All option grants are amortized over the requisite service period of the awards on a straight-line basis. Expected volatility is based on historical volatility. The expected life of options granted is based on historical expected life. The risk-free interest rate is based on the United States Treasury yield in effect at the time of grant with maturities appropriate for the expected term of the stock option. The forfeiture rate is based on historical data and Inovio records stock-based compensation expense only for those awards that are expected to vest. The dividend yield is based on the fact that no dividends have been paid on common stock historically, and none are currently expected to be paid.
Weighted average assumptions used in the Black-Scholes model for employees and directors are presented below:
	Year Ended December 31,
	2013	2012		2011
Risk-free interest rate	0.41%	0.36%		1.23%
Expected volatility	111%	131%		134%
Expected life in years	4	4		4
Dividend yield	—	—		—
Forfeiture rate	8%	8%		11%
Assumptions used in the Black-Scholes model for non-employees are presented below:
	Year Ended December 31,
	2013	2012		2011
Risk-free interest rate	0.84% – 1.52%	0.67% – 0.83%		0.91% – 3.47%
Expected volatility	102%-113%	103%-117%		96%-119%
Expected life in years	10-Jul	10-Jul		10-Jun
Dividend yield	—	—		—
Recent Accounting Pronouncements
The below recent pronouncement may have a significant effect on the Company's financial statements. Recent pronouncements that are not anticipated to have an impact on or are unrelated to the Company's financial condition, results of operations, or related disclosures are not discussed.
Accounting Standards Update (“ASU”), No. 2013-02-In February 2013, the Financial Accounting Standards Board (“FASB”) issued an ASU which amended the disclosure requirements regarding the reporting of amounts reclassified out of accumulated other comprehensive income. The amendment does not change the current requirement for reporting net income or other comprehensive income, but requires additional disclosures about significant amounts reclassified out of accumulated other comprehensive income including the effect of the reclassification on the related net income line items. The Company has adopted ASU 2013-02 prospectively effective January 1, 2013 and the adoption is not expected to have a significant impact on the Company's financial statements as the requirements are disclosure only in nature.

Collaborative_Agreements

Collaborative Agreements	12 Months Ended
	Dec. 31, 2013
Organization, Consolidation and Presentation of Financial Statements [Abstract]	'
Collaborative Agreements	'
	Collaborative Agreements
	In September 2013, the Company entered into a Collaborative, License, and Option Agreement (the “Agreement”) with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. (“Roche”). Under the Agreement, the Company and Roche will co-develop multi-antigen DNA immunotherapies targeting prostate cancer and hepatitis B (the “Products”).
	Roche acquired an exclusive worldwide license for the Company's DNA-based vaccines INO-5150 (targeting prostate cancer) and INO-1800 (targeting hepatitis B) as well as the use of the Company's CELLECTRA® electroporation technology for delivery of the vaccines. Roche also obtained an option to license additional vaccines in connection with a collaborative research program in prostate cancer.
	Under the terms of the Agreement, Roche made an upfront payment of $10 million and has agreed to make additional development, regulatory and commercial event based payments of up to $412.5 million, of which $3.0 million related to INO-1800 represent milestones under the milestone method of accounting. Additional event based payments could also be made to the Company if Roche pursues other indications with INO-5150 or INO-1800. The Company has assessed event based payments under the revised authoritative guidance for research and development milestones and determined that other than the $3.0 million related to INO-1800 discussed above, none of the other event based payments represent milestones under the milestone method of accounting. No event based payments or milestones were achieved during the periods presented.
	The Company is entitled to receive up to double-digit tiered royalties on product sales. Unless terminated earlier in accordance with its terms, the Agreement continues in effect until the date when no royalty or other payment obligations under the Agreement are or will become due, i.e., a royalty term ending on the later of the date that is (a) ten years after the date of the first commercial sale of the product that is subject to the Agreement or (b) the expiration of the last to expire of the patent rights that are subject to the Agreement. Under the terms of the Agreement the Company also agreed to perform certain research and development and manufacturing and supply services, at Roche's expense.
	The Company identified the deliverables at the inception of the agreement. The Company has determined that the license to INO-5150 and INO-1800, the Option Right to license additional vaccines, research and development services, manufacturing and drug supply, and participation in the Joint Steering Committee individually represent separate units of accounting because each deliverable has standalone value. The Company considered the provisions of the multiple-element arrangement guidance in determining whether the deliverables outlined above have standalone value and thus should be treated as separate units of accounting. The Company determined that the licenses and Option Right to license additional vaccines have standalone value and represent separate units of accounting because the rights conveyed permit Roche to perform all efforts necessary to complete development, commercialize and begin selling the product upon regulatory approval. In addition, Roche has the appropriate development, regulatory and commercial expertise with products similar to the product licensed under the agreement and has the ability to engage third parties to manufacture the product allowing Roche to realize the value of the license without receiving any of the remaining deliverables. Roche can also sublicense its license rights to third parties. Also, the Company determined that the research services, committee participation and manufacturing services each represent individual units of accounting as Roche could perform such services and/or could acquire these on a separate basis. The best estimated selling prices for these units of accounting were determined based on market conditions, the terms of comparable collaborative agreements for similar technology in the pharmaceutical and biotechnology industry, the Company's pricing practices and pricing objectives and the nature of the research and development services to be provided. While market data was considered throughout the valuation process, ultimately, the selling prices of the licenses and Option Right were determined utilizing two forms of the relief from royalty method under the Income Approach and the cost-to-recreate method under the Cost Approach. The arrangement consideration was allocated to the deliverables based on the relative selling price method.
	The amount allocable to the delivered unit or units of accounting is limited to the amount that is considered fixed and determinable and is not contingent upon the delivery of additional items or meeting other specified performance conditions. Based on the results of the Company's analysis, the $10 million up-front payment was allocated as follows: $5.0 million and $3.4 million to the license to INO-5150 and INO-1800, respectively, $1.5 million to the Option Right and $155,000 to the Joint Steering Committee obligation. The amounts allocated to the licenses for INO-5150 and INO-1800 were recognized as revenue under collaborative research and development arrangements during the year ended December 31, 2013 as these were determined to be earned upon the granting of the license and delivery of the related knowledge and data. Due to the Company's continuing involvement obligations, the remaining amounts will be classified as deferred revenue as of December 31, 2013. The Company will recognize revenues associated with research and development services and manufacturing and drug supply as revenues under collaborative arrangements as the related services are performed and according to the relative selling price method of the allocable arrangement consideration. During the year ended December 31, 2013, the Company recognized revenues of $9.2 million from Roche, of which $9.1 million was allocated to the licenses and $84,000 to research and development services and manufacturing, respectively. As of December 31, 2013, the Company has a deferred revenue balance of $3.4 million related to the Roche Agreement.
	The Company has entered into various Collaborative Development and License Agreements with VGX Int’l as discussed in Note 15. Under these Agreements, the Company may receive future event based payments upon approval of an investigational new drug application (IND) and/or initiation of clinical trials and future net sales. These future event based payments do not meet the criteria of a milestone in accordance with the authoritative guidance as they are solely based on the performance of the collaborators.

Investments

Investments	12 Months Ended
	Dec. 31, 2013
Investments, Debt and Equity Securities [Abstract]	'
Investments	'
	Investments
	Investments consist of mutual funds and municipal bonds at December 31, 2013 and of certificates of deposit, mutual funds, and municipal bonds at December 31, 2012. The Company classifies all investments as available-for-sale, as the sale of such investments may be required prior to maturity to implement management strategies. These investments are carried at fair value, with the unrealized gains and losses reported as a component of accumulated other comprehensive loss in the consolidated statements of stockholders’ equity until realized. Realized gains and losses from the sale of investments, if any, are determined on a specific identification basis. Realized gains and losses and declines in value judged to be other-than-temporary, if any, on available-for-sale investments are included as a component of interest and other income, net, in the consolidated statements of operations. During the year ended December 31, 2013, net realized loss on investments of $39,000 was recorded. No such impairment charges were recorded during the years ended December 31, 2012 or 2011. Interest on investments classified as available-for-sale are included in interest and other income, net, in the consolidated statements of operations.
	The following is a summary of short-tem investments as of December 31, 2013 and 2012:
			As of December 31, 2013
		Contractual	Cost		Gross Unrealized		Gross Unrealized			Fair Market Value
		Maturity (in years)			Gains		Losses
	Mutual funds	---	$	18,178,518	$	—	$	(78,614	)	$	18,099,904
	Municipal bonds	Less than 1	805,144		560		—			805,704
	Total investments		$	18,983,662	$	560	$	(78,614	)	$	18,905,608
			As of December 31, 2012
		Contractual	Cost		Gross Unrealized		Gross Unrealized			Fair Market Value
		Maturity (in years)			Gains		Losses
	Mutual funds	---	$	7,500,063	$	83,868	$	—		$	7,583,931
	Certificates of deposit	Less than 1	250,000		—		—			250,000
	Municipal bonds	Less than 1	201,470		—		(1,400		)	200,070
	Total investments		$	7,951,533	$	83,868	$	(1,400	)	$	8,034,001

Fair_Value_Measurements

Fair Value Measurements	12 Months Ended
	Dec. 31, 2013
Fair Value Disclosures [Abstract]	'
Fair Value Measurements	'
	Fair Value Measurements
	The guidance regarding fair value measurements establishes a three-tier fair value hierarchy which prioritizes the inputs used in measuring fair value. These tiers include: Level 1, defined as observable inputs such as quoted prices in active markets; Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable; and Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions.
	Assets and liabilities are classified based on the lowest level of input that is significant to the fair value measurements. The Company reviews the fair value hierarchy classification on a quarterly basis. Changes in the ability to observe valuation inputs may result in a reclassification of levels for certain securities within the fair value hierarchy. The Company did not have any transfer of assets and liabilities between Level 1, Level 2 and Level 3 of the fair value hierarchy during the years ended December 31, 2013 and 2012.
	The following table presents the Company’s assets and liabilities that are measured at fair value on a recurring basis as of December 31, 2013:
		Fair Value Measurements at
		December 31, 2013
		Total			Using Quoted Prices			Using Significant		Using Significant
					in Active Markets			Other Unobservable		Unobservable
					for Identical Assets			Inputs		Inputs
					(Level 1)			(Level 2)		(Level 3)
	Assets:
	Money market funds	$	26,852,560		$	26,852,560				$	—
	Mutual funds	18,099,904			—			18,099,904		—
	Municipal bonds	805,704			—			805,704		—
	Investment in affiliated entity	9,664,587			9,664,587			—		—
	Common stock warrants	717,500			—			—		717,500
	Total Assets	$	56,140,255		$	36,517,147		$	18,905,608	$	717,500
	Liabilities:
	Common stock warrants	$	19,540,583		$	—		$	—	$	19,540,583
	Total Liabilities	$	19,540,583		$	—		$	—	$	19,540,583
	The following table presents the Company’s assets and liabilities that are measured at fair value on a recurring basis as of December 31, 2012:
		Fair Value Measurements at
		December 31, 2012
		Total			Using Quoted Prices			Using Significant		Using Significant
					in Active Markets			Other Unobservable		Unobservable
					for Identical Assets			Inputs		Inputs
					(Level 1)			(Level 2)		(Level 3)
	Assets:
	Money market funds	$	1,686,406		$	1,686,406		$	—	$	—
	Mutual funds	7,583,931			—			7,583,931		—
	Certificates of deposit	250,000			—			250,000		—
	Municipal bonds	200,070			—			200,070		—
	Investment in affiliated entity	10,703,332			10,703,332			—		—
	Common stock warrants	267,200			—			—		267,200
	Total Assets	$	20,690,939		$	12,389,738		$	8,034,001	$	267,200
	Liabilities:
	Common stock warrants	$	2,859,899		$	—		$	—	$	2,859,899
	Total Liabilities	$	2,859,899		$	—		$	—	$	2,859,899
	Level 1 assets include money market funds held by the Company that are valued at quoted market prices, as well as the Company’s investment in VGX Int’l, for which the fair value is based on the market value of 8,220,775 common shares on December 31, 2013 and 2012, listed on the Korean Stock Exchange. The Company accounts for its investment at fair value on a recurring basis.
	Level 2 assets at December 31, 2013 include mutual funds held by the Company that are initially valued at the transaction price and subsequently valued, at the end of each reporting period, typically utilizing market observable data. The Company obtains the fair value of its Level 2 assets from a professional pricing service, which may use quoted market prices for identical or comparable instruments, or inputs other than quoted prices that are observable either directly or indirectly. The professional pricing service gathers quoted market prices and observable inputs for all of mutual funds from a variety of industry data providers. The valuation techniques used to measure the fair value of the Company's Level 2 financial instruments were derived from non-binding market consensus prices that are corroborated by observable market data, quoted market prices for similar instruments, or pricing models such as discounted cash flow techniques. The Company validates the quoted market prices provided by the primary pricing service by comparing their assessment of the fair values of the Company's investment portfolio balance against the fair values of the Company's investment portfolio balance obtained from an independent source.
	Level 3 assets at December 31, 2013 include two warrants received by the Company to purchase shares of common stock of OncoSec Medical Incorporated (“OncoSec”), in connection with the first and second amendments to the Asset Purchase Agreement between the Company and OncoSec signed in September 2011 and March 2012, respectively. The first warrant to purchase 1,000,000 shares of common stock of OncoSec has a contractual life of five years with an exercise price of $1.20 per share. The second warrant to purchase 3,000,000 shares of common stock of OncoSec has a contractual life of five years with an exercise price of $1.00 per share.
	As of December 31, 2013 the Company recorded a long-term asset of approximately $718,000 associated with the warrants received to purchase common stock of OncoSec. The Company valued the warrants received in March 2012 as of the issuance date using the Black Scholes pricing model and recorded a $501,000 gain on sale of assets within the consolidated statement of operations. Inputs used in the pricing model include estimates of OncoSec stock price volatility, expected warrant life and risk-free interest rate. The Company develops its estimates based on publicly available historical data and knowledge of OncoSec. The Company reassesses the fair value of the warrants at each reporting date. The assumptions used to estimate the fair values of the OncoSec common stock warrants at December 31, 2013 are presented below:
	Risk-free interest rate	0.78%
	Expected volatility	85%
	Expected life in years	2.75-3.25
	Dividend yield	—
	As a result of these calculations, the Company recorded an increase (decrease) in fair value of the two warrants of $450,000 and ($334,000) for the years ended December 31, 2013 and 2012, respectively. The change in fair value is reflected in the Company's consolidated statement of operations as a component of change in fair value of common stock warrants.
	The following table presents a summary of changes in fair value of the Company’s total Level 3 financial assets for the years ended December 31, 2013 and 2012:
		Year Ended			Year Ended
		December 31, 2013			December 31, 2012
	Balance at beginning of year	$	267,200		$	100,000
	Common stock warrant recorded at fair value upon acquisition	—			501,000
	Increase (Decrease) in fair value included in change in fair value of common stock warrants	450,300			(333,800		)
	Balance at end of year	$	717,500		$	267,200
	Level 3 liabilities held as of December 31, 2013 consist of common stock warrant liabilities associated with warrants to purchase the Company's common stock issued in July 2009, January 2011 and March 2013. Level 3 liabilities held as of December 31, 2012 consist of common stock warrant liabilities associated with warrants to purchase the Company's common stock issued in July 2009, January 2011 and December 2011. During the year ended December 31, 2013, warrants to purchase 21,164,997 shares of common stock were exercised.
	As of December 31, 2013 the Company recorded a $19.5 million common stock warrant liability. The Company reassesses the fair value of the common stock warrants at each reporting date utilizing a Black-Scholes pricing model. Inputs used in the pricing model include estimates of stock price volatility, expected warrant life and risk-free interest rate. The Company develops its estimates based on historical data. The range of assumptions used to estimate the fair values of common stock warrants at December 31, 2013 are presented below:
	Risk-free interest rate	0.13%-1.75%
	Expected volatility	90%-112%
	Expected life in years	.50-4.70
	Dividend yield	—
	Changes in these assumptions as well as in the Company's stock price on the valuation date can have a significant impact on the fair value of the common stock warrant liability. As a result of these calculations, the Company recorded an increase (decrease) in fair value of $46.1 million, $(2.3) million and $(8.8) million for the years ended December 31, 2013, 2012 and 2011, respectively. The significant change in fair value was primarily due to the change in the Company's stock price during the period. The change in fair value is reflected in the Company's consolidated statement of operations as a component of change in fair value of common stock warrants. Warrants that were exercised during the period were revalued on the day prior to exercise and then reclassified into stockholders' equity upon exercise.
	The following table presents the changes in fair value of the Company’s total Level 3 financial liabilities for the years ended December 31, 2013 and 2012:
		Year Ended			Year Ended
	December 31,			December 31,
	2013			2012
Balance at beginning of year	$	2,859,899		$	5,176,319
Record fair value of warrants issued in March 2013 financing	5,968,244			—
Increase (Decrease) in fair value included in change in fair value of common stock warrants	46,082,969			(2,316,420		)
Change in classification from liability to stockholders' equity due to warrant exercises	(35,370,529		)	—
Balance at end of year	$	19,540,583		$	2,859,899

Major_Customers_and_Concentrat

Major Customers and Concentration of Credit Risk	12 Months Ended
	Dec. 31, 2013
Risks and Uncertainties [Abstract]	'
Major Customers and Concentration of Credit Risk	'
	Major Customers and Concentration of Credit Risk
	Customer	2013		% of Total		2012		% of Total		2011		% of Total
				Revenue				Revenue				Revenue
	Roche	$	9,181,759	68	%	$	—	—	%	$	—	—	%
	NIAID	2,090,939		16		2,831,115		69	%	7,801,976		80	%
	VGX Int'l (affiliated entity)	425,000		3		577,467		14		411,459		4
	All other	1,769,648		13		710,070		17		1,581,822		16
	Total Revenue	$	13,467,346	100	%	$	4,118,652	100	%	$	9,795,257	100	%
	During the years ended December 31, 2013, 2012 and 2011, the Company recognized revenue from various license fees and milestone payments, collaborative research and development agreements, grants and government contracts. As of December 31, 2013, $2.6 million or 79% and $382,000 or 12% of accounts receivable was attributed to Roche and the NIAID, respectively. As of December 31, 2012, $612,000 or 71% and $95,000 or 11% of accounts receivable was attributed to the NIAID and University of Pennsylvania, respectively.
	There is minimal credit risk with these customers based upon collection history, their size and financial condition. Accordingly, the Company does not consider it necessary to record a reserve for uncollectible accounts receivable.

Fixed_Assets_Fixed_Assets

Fixed Assets Fixed Assets	12 Months Ended
	Dec. 31, 2013
Property, Plant and Equipment [Abstract]	'
Fixed Assets	'
	Fixed Assets
	Fixed assets at December 31, 2013 and 2012 consist of the following:
		Cost		Accumulated			Net Book
				Depreciation			Value
				and
				Amortization
	As of December 31, 2013
	Machinery, equipment and office furniture	$	2,381,033	$	(1,807,706	)	$	573,327
	Leasehold improvements	2,420,940		(107,722		)	2,313,218
		$	4,801,973	$	(1,915,428	)	$	2,886,545
	As of December 31, 2012
	Machinery, equipment and office furniture	$	2,014,588	$	(1,731,660	)	$	282,928
	Leasehold improvements	466,135		(386,042		)	80,093
		$	2,480,723	$	(2,117,702	)	$	363,021
	Depreciation expense for the years ended December 31, 2013, 2012 and 2011 was $329,000, $174,000 and $142,000, respectively. The Company determined that the carrying value of these long-lived assets was not impaired for the periods presented.

Goodwill_and_Intangible_Assets

Goodwill and Intangible Assets	12 Months Ended
	Dec. 31, 2013
Goodwill and Intangible Assets Disclosure [Abstract]	'
Goodwill and Intangible Assets	'
	Goodwill and Intangible Assets
	The following sets forth the goodwill and intangible assets by major asset class:
				December 31, 2013							December 31, 2012
		Useful		Gross		Accumulated			Net Book		Gross		Accumulated			Net Book
		Life				Amortization			Value				Amortization			Value
		(Yrs)
	Non-Amortizing:
	Goodwill(a)			$	10,113,371	$	—		$	10,113,371	$	10,113,371	$	—		$	10,113,371
	Amortizing:
	Patents	8 – 17		5,802,528		(5,128,227		)	674,301		5,802,528		(4,852,673		)	949,855
	Licenses	8 – 17		1,323,761		(1,075,617		)	248,144		1,323,761		(1,046,870		)	276,891
	CELLECTRA®(b)	5 – 11		8,106,270		(5,543,786		)	2,562,484		8,106,270		(4,334,234		)	3,772,036
	GHRH(b)	11		335,314		(145,215		)	190,099		335,314		(113,531		)	221,783
	Other(c)	18		4,050,000		(2,006,250		)	2,043,750		4,050,000		(1,781,250		)	2,268,750
	Total intangible assets			19,617,873		(13,899,095		)	5,718,778		19,617,873		(12,128,558		)	7,489,315
	Total goodwill and intangible assets			$	29,731,244	$	(13,899,095	)	$	15,832,149	$	29,731,244	$	(12,128,558	)	$	17,602,686
	(a)	Goodwill was recorded from the Inovio AS acquisition in January 2005 and from the acquisition of VGX in June 2009 for $3.9 million and $6.2 million, respectively.
	(b)	CELLECTRA® and GHRH are developed technologies which were recorded from the acquisition of VGX.
	(c)	Other intangible assets represent the fair value of acquired intellectual property from the Inovio AS acquisition.
	Aggregate amortization expense on intangible assets was $1.8 million, $1.8 million and $1.9 million for the years ended December 31, 2013, 2012 and 2011, respectively. Amortization expense related to intangible assets at December 31, 2013 for each of the next five fiscal years and beyond is expected to be incurred as follows:
	2014	$	943,000
	2015	870,000
	2016	816,000
	2017	775,000
	2018	773,000
	Thereafter	1,542,000
		$	5,719,000
	In accordance with the guidance regarding goodwill, the Company has completed its annual impairment test and fair value analysis for goodwill held throughout the year. The Company conducts the impairment test annually on November 30th. There was no impairment or impairment indicator present and no loss was recorded during the years ended December 31, 2013, 2012 and 2011, respectively.

Accounts_Payable_and_Accrued_E

Accounts Payable and Accrued Expenses	12 Months Ended
	Dec. 31, 2013
Payables and Accruals [Abstract]	'
Accounts Payable and Accrued Expenses	'
	Accounts Payable and Accrued Expenses
	Accounts payable and accrued expenses at December 31, 2013 and 2012 consist of the following:
		As of		As of
		December 31,		December 31,
		2013		2012
	Trade accounts payable	$	1,865,723	$	852,573
	Accrued compensation	2,586,806		1,560,704
	Other accrued expenses	991,979		768,297
		$	5,444,508	$	3,181,574

Stockholders_Equity

Stockholders' Equity	12 Months Ended
	Dec. 31, 2013
Stockholders' Equity Note [Abstract]	'
Stockholders' Equity	'
	Stockholders’ Equity
	Preferred Stock
								Outstanding
								as of
								December 31,
		Authorized			Issued			2013		2012
	Series A Preferred Stock, par $0.001	1,000			817			—		—
	Series B Preferred Stock, par $0.001	1,000			750			—		—
	Series C Preferred Stock, par $0.001	1,091			1,091			26		26
	Series D Preferred Stock, par $0.001	1,966,292			1,966,292			—		—
	There have been no changes in the number of outstanding shares of our preferred stock for the years ended December 31, 2013, 2012 or 2011.
	The shares of the Company’s outstanding Series C Preferred Stock have the following pertinent rights and privileges, as set forth in the Company’s Amended and Restated Certificate of Incorporation and its Certificates of Designations, Rights and Preferences related to the various series of preferred stock.
	Rights on Liquidation
	In the event of any voluntary or involuntary liquidation, dissolution or winding up of the Company (a “liquidation event”), before any distribution of assets of the Company shall be made to or set apart for the holders of common stock, the holders of Series C Preferred Stock, pari passu, are entitled to receive payment of such assets of the Company in an amount equal to $10,000 per share of such series of preferred stock, plus any accumulated and unpaid dividends thereon (whether or not earned or declared).
	If the assets of the Company available for distribution to stockholders exceed the aggregate amount of the liquidation preferences payable with respect to all shares of each series of preferred stock then outstanding, then, after the payment of such preferences is made or irrevocably set aside, the holders of the Company’s common stock are entitled to receive a pro rata portion of such assets based on the aggregate number of shares of common stock held by each such holder. The holders of the Company’s outstanding preferred stock shall participate in such a distribution on a pro-rata basis, computed based on the number of shares of common stock which would be held by such preferred holders if immediately prior to the liquidation event all of the outstanding shares of the preferred stock had been converted into shares of common stock at the then current conversion value applicable to each series.
	A Change of Control of the Company (as defined in the Certificates of Designations, Rights and Preferences) is not a liquidation event triggering the preferences described above, and is instead addressed by separate terms in the Series C Certificates of Designations, Rights, and Preferences.
	Although the liquidation preferences are in excess of the par value of $0.001 per share of the Company’s preferred stock, these preferences are equal to or less than the stated value of such shares based on their original purchase price.
	Voting Rights
	The holders of all series of the Company’s preferred stock outstanding have full voting rights and powers equal to the voting rights and powers of holders of the Company’s common stock and are entitled to notice of any stockholders’ meeting in accordance with the Company’s Bylaws. Holders of the Company’s preferred stock are entitled to vote on any matter upon which holders of the Company’s common stock have the right to vote, including, without limitation, the right to vote for the election of directors together with the holders of common stock as one class.
	Conversion Rights
	The Series C Preferred Stock each provide the holder of such shares an optional conversion right and provide a mandatory conversion upon certain triggering events.
	Right to Convert The holder of any share or shares of Series C Preferred Stock has the right at any time, at such holder’s option, to convert all or any lesser portion of such holder’s shares of the Preferred Stock into such number of fully paid and non-assessable shares of Common Stock as is determined by dividing (i) the aggregate Liquidation Preference applicable to the particular series of preferred shares, plus accrued and unpaid dividends thereon by (ii) the applicable Conversion Value (as defined in the relevant series’ Certificate of Designations, Rights and Preferences) then in effect for such series of preferred shares. The Company is not obligated to issue any fractional shares or scrip representing fractional shares upon such conversion and instead shall pay the holder an amount in cash equal to such fraction multiplied by the current market price per share of the Company’s common stock.
	Mandatory Conversion The Company has the option upon thirty (30) days prior written notice, to convert all of the outstanding shares of the Series C Preferred Stock into such number of fully paid and non-assessable shares of common stock as is determined by dividing (i) the aggregate Liquidation Preference of the shares of the relevant series of preferred stock to be converted plus accrued and unpaid dividends thereon by (ii) the applicable Conversion Value (as defined in the relevant series’ Certificate of Designations, Rights and Preferences) then in effect, if at any time after twelve months following the Original Issue Date of each such series of preferred stock all of the following triggering events occur:
	(i) The registration statement covering all of the shares of common stock into which the particular series of preferred stock is convertible is effective (or all of the shares of common stock into which the preferred stock is convertible may be sold without restriction pursuant to Rule 144 under the Securities Act of 1933, as amended);
	(ii) the Daily Market Price (as defined in the applicable Certificates of Designations, Rights and Preferences) of the common stock crosses a specified pricing threshold for twenty of the thirty consecutive trading days prior to the date the Company provides notice of conversion to the holders; and
	(iii) the average daily trading volume (subject to adjustment for stock dividends, subdivisions and combinations) of the common stock for at least twenty of the thirty consecutive trading days prior to the date the Company provides notice of conversion to the holders exceeds 25,000 shares.
	As of December 31, 2013, our outstanding shares of the Series C Preferred Stock were convertible into 38,233 shares of our common stock at a conversion price of $6.80 per share, and the applicable Daily Market Price of the common stock for triggering mandatory conversion equaled $18.00 per share.
	Common Stock
	In May 2013, the Company filed a Certificate of Amendment to the Certificate of Incorporation with the Delaware Secretary of State. The Certificate of Amendment increased the number of shares of common stock the Company has the authority to issue from 300,000,000 shares to 600,000,000 shares.
	In March 2013, the Company completed an underwritten offering of 27,377,266 shares of common stock and warrants to purchase an aggregate of up to 13,688,633 shares of common stock. The shares and warrants were sold in units at a price of $0.55 per unit, with each unit consisting of one share of common stock and a warrant to purchase 0.50 share of common stock at an exercise price of $0.7936 per share. The warrants have a term of five and one-half years. The net proceeds, after deducting the underwriters' discounts and other offering expenses, were approximately $14.0 million. The Company valued the registered warrants issued in connection with the March 2013 financing as of the issuance date using the Black Scholes pricing model and recorded a current liability on the consolidated balance sheet of $6.0 million. The warrants were subsequently revalued and the Company recorded the increase in fair value of $25.0 million to change in fair value of common stock warrants on the consolidated statement of operations for the year ended December 31, 2013. As of December 31, 2013, 10,665,908 of these warrants had been exercised. Transaction costs associated with the issuance of the warrants were allocated by using the relative fair value approach. These transaction costs of $316,000 were immediately expensed and included as part of general and administrative expense in the Company's consolidated statement of operations for the year ended December 31, 2013.
	In June 2012, the Company entered into a sales agreement (the “Sales Agreement”) with an outside placement agent (the “Placement Agent”) to sell shares of its common stock with aggregate gross proceeds of up to $25.0 million from time to time, through an “at-the-market” equity offering program under which the Placement Agent will act as sales agent. Under the Sales Agreement, the Company will set the parameters for the sale of shares, including the number of shares to be issued, the time period during which sales are requested to be made, limitation on the number of shares that may be sold in any one trading day and any minimum price below which sales may not be made. The Sales Agreement provides that the Placement Agent will be entitled to compensation for its services in an amount equal to 3.0% of the gross proceeds from the sales of shares sold through the Placement Agent under the Sales Agreement. The Company has no obligation to sell any shares under the Sales Agreement, and may at any time suspend solicitation and offers under the Sales Agreement.
	During the year ended December 31, 2013, the Company sold a total of 15,700,668 shares of common stock under the Sales Agreement. The sales were made at a weighted average price of $1.24 per share with net proceeds to the Company of $18.9 million. As of December 31, 2013, the Company has exhausted all available proceeds under this Sales Agreement.
	During the year ended December 31, 2012, the Company sold a total of 9,344,611 shares of common stock under the Sales Agreement. The sales were made at a weighted average price of $0.59 per share with net proceeds to the Company of $5.3 million.
	In December 2011, the Company completed an underwritten public offering relating to the sale and issuance of 7,699,712 units to certain institutional investors, consisting of 7,699,712 shares of common stock and warrants to purchase an aggregate of up to 5,774,784 additional shares of common stock. These units, which were purchased for $0.5195 per unit, include the partial exercise of the underwriter's overallotment option of 962,465 additional units at the public offering price. The units consist of one share of common stock and 0.75 of a warrant to purchase one share of common stock. The warrants have a term of five years and an exercise price of $0.65 per share. The Company may call the warrants if the closing bid price of the common stock has been at least $1.30 over 20 trading days and certain other conditions are met. The Company received net proceeds from the transaction of approximately $3.7 million, after deducting the underwriter's discounts and other offering expenses payable by the Company. The Company valued the registered warrants issued in connection with the December 2011 financing as of the issuance date using the Black Scholes pricing model and recorded a current liability on the consolidated balance sheet. The warrants were subsequently revalued and the Company recorded the change in fair value of $(4.9) million and $115,000 to change in fair value of common stock warrants on the consolidated statement of operations for the years ended December 31, 2013 and 2012, respectively. As of December 31, 2013, all of these warrants had been exercised.
	In January 2011, the Company entered into investor purchase agreements with investors relating to the issuance and sale of (a) 21,130,400 shares of common stock, and (b) warrants to purchase a total of 10,565,200 shares of common stock with an exercise price of $1.40 per share, for an aggregate purchase price of approximately $24.3 million. The shares of common stock and warrants were sold in units, consisting of one share of common stock and a warrant to purchase 0.50 of a share of common stock, at a purchase price of $1.15 per unit. The Warrants have a five-year term from the date of issuance and are first exercisable commencing on the 180th day after the date of issuance. The Company may call the warrants if the closing bid price of the common stock has been at least $2.80 over 20 trading days and certain other conditions are met. The Company received net proceeds from the transaction of approximately $23.0 million, after deducting the placement agent's fee and offering expenses payable by the Company. The Company valued the registered warrants issued in connection with the January 2011 financing as of the issuance date using the Black Scholes pricing model and recorded a current liability on the consolidated balance sheet. The warrants were subsequently revalued and the Company recorded the change in fair value of $(15.8) million and $2.4 million to change in fair value of common stock warrants on the consolidated statement of operations for the years ended December 31, 2013 and 2012, respectively. As of December 31, 2013, 3,870,200 of these warrants had been exercised.
	The Company accounts for registered common stock warrants issued in July 2009, January 2011 and March 2013 under the authoritative guidance on accounting for derivative financial instruments indexed to, and potentially settled in, a company’s own stock, on the understanding that in compliance with applicable securities laws, the registered warrants require the issuance of registered securities upon exercise and do not sufficiently preclude an implied right to net cash settlement. The Company classifies registered warrants on the consolidated balance sheet as a current liability which is revalued at each balance sheet date subsequent to the initial issuance. Determining the appropriate fair-value model and calculating the fair value of registered warrants requires considerable judgment, including estimating stock price volatility and expected warrant life. The Company develops its estimates based on historical data. A small change in the estimates used may have a relatively large change in the estimated valuation. The Company uses the Black-Scholes pricing model to value the registered warrants. Changes in the fair market value of the warrants are reflected in the consolidated statement of operations as “Change in fair value of common stock warrants.”
	Warrants
	The following table summarizes the warrants outstanding as of December 31, 2013 and 2012:
									As of December 31, 2013					As of December 31, 2012
	Issued in Connection With:		Exercise				Expiration		Number of		Common Stock			Number of	Common Stock
			Price				Date		Warrants		Warrant Liability			Warrants	Warrant Liability
	March 2013 financing		$	0.79			September 12, 2018		3,022,725		$	7,859,085		—	$	—
	December 2011 financing		$	0.65			6-Dec-16		—		—			5,774,784	2,078,921
	January 2011 financing		$	1.4			January 27, 2016		6,695,000		11,381,498			10,565,200	779,711
	July 2009 financing		$	3.38			1-Jul-14		333,333		300,000			333,333	1,267
	Warrants assumed in June 2009 Merger		$1.02-$1.28				August 1, 2015-		4,008,202		—			4,920,527	—
							28-Apr-16
	Total								14,059,260		$	19,540,583		21,593,844	$	2,859,899
	During the year ended December 31, 2013, warrants to purchase 10,665,908 shares of the Company's common stock which were issued in connection with the March 2013 financing were exercised, with proceeds to the Company of $8.5 million.
	During the year ended December 31, 2013, warrants to purchase 5,774,784 shares of the Company's common stock which were issued in connection with the December 2011 financing were exercised, with proceeds to the Company of $3.8 million.
	During the year ended December 31, 2013, warrants to purchase 3,870,200 shares of the Company's common stock which were issued in connection with the January 2011 financing were exercised, with proceeds to the Company of $5.4 million.
	During the year ended December 31, 2013, warrants expired to purchase 58,220 shares of the Company's common stock, which were assumed in the June 2009 Merger.
	In August 2012, warrants expired to purchase 150,000 shares of our common stock issued in connection with consulting
	services received in August 2007.
	Stock Options
	The Company has one active stock-based incentive plan, the Amended and Restated 2007 Omnibus Incentive Plan (the “Incentive Plan”), pursuant to which the Company has granted stock options and restricted stock awards to executive officers, directors and employees. The Incentive Plan was adopted on March 31, 2007, approved by the stockholders on May 4, 2007, approved by the stockholders as amended on May 2, 2008, and approved by the stockholders as amended and restated on August 25, 2009 and May 14, 2010. On May 14, 2010 the stockholders approved to increase the aggregate number of shares available for grant under the Incentive Plan by 2,000,000 and to provide that the aggregate number of shares available for grant under the Incentive Plan will be increased on January 1 of each year beginning in 2011 by a number of shares equal to the lesser of (1) 2,055,331 or (2) such lesser number of shares as may be determined by the Board. At December 31, 2013, the Incentive Plan reserves 11,915,993 shares of common stock for issuance as or upon exercise of incentive awards granted and to be granted at future dates. At December 31, 2013, the Company had 1,197,306 shares of common stock available for future grant under the Incentive Plan, and 240,000 shares of vested restricted stock and options to purchase 9,163,063 shares of common stock outstanding under the Incentive Plan. The awards granted and available for future grant under the Incentive Plan generally vest over three years and have a maximum contractual term of ten years. The Incentive Plan terminates by its terms on March 31, 2017.
	The Incentive Plan supersedes all of the Company’s previous stock option plans, which include the Amended 2000 Stock Option Plan and the VGX Equity Compensation Plan, under which the Company had options to purchase 1,091,750 and 6,283,305 shares of common stock outstanding at December 31, 2013, respectively. The terms and conditions of the options outstanding under these plans remain unchanged.
	Total compensation cost for our stock plans recognized in the consolidated statement of operations for the years ended December 31, 2013, 2012 and 2011 was $1.2 million, $1.2 million, and $1.6 million, respectively, of which $550,000, $555,000 and $472,000 was included in research and development expenses and $605,000, $638,000 and $1.1 million was included in general and administrative expenses, respectively.
	At December 31, 2013 and 2012, there was $956,000 and $944,000 of total unrecognized compensation cost, respectively, related to unvested stock options, which is expected to be recognized over a weighted-average period of 1.8 years and 1.9 years, respectively.
	The fair value of options granted to non-employees at the measurement dates were estimated using the Black-Scholes pricing model. Total stock-based compensation for options granted to non-employees for the years ended December 31, 2013, 2012 and 2011 was $714,000, $153,000 and $33,000, respectively. As of December 31, 2013, 4,794,496 non-employee options remained outstanding.
	The following table summarizes total stock options outstanding at December 31, 2013:
			Options Outstanding								Options Exercisable
	Exercise Price		Options			Weighted-Average		Weighted			Options		Weighted-Average
Outstanding			Remaining	Average		Exercisable		Exercise Price
			Contractual Life	Exercise Price
			(in Years)
$0.00 – $1.00		5,888,591			8.2		$	0.56		2,561,431		$	0.57
$1.01 – $2.00		9,363,064			4.1		$	1.32		8,903,626		$	1.32
$2.01 – $4.00		1,047,713			3.1		$	3.02		986,307		$	3.06
$4.01 – $6.00		188,750			0.3		$	4.86		188,750		$	4.86
$6.01 – $6.12		50,000			0.2		$	6.12		50,000		$	6.12
		16,538,118			5.5		$	1.21		12,690,114		$	1.38
At December 31, 2013, the aggregate intrinsic value of options outstanding was $28.7 million, the aggregate intrinsic value of options exercisable was $20.1 million, and the weighted average remaining contractual term of options exercisable was 4.7 years.
At December 31, 2013, 3,540,163 stock options are expected to vest.
Stock option activity under our stock option plans was as follows:
	Number of			Weighted-Average
	Shares			Exercise Price
Balance, December 31, 2010	12,649,968			$	1.49
Granted	2,068,750			1.1
Exercised	(68,309	)		0.23
Cancelled	(347,606	)		2.25
Balance, December 31, 2011	14,302,803			1.42
Granted	2,733,750			0.58
Exercised	—			—
Cancelled	(779,109	)		1.55
Balance, December 31, 2012	16,257,444			1.28
Granted	2,913,625			0.61
Exercised	(1,925,214	)		0.81
Cancelled	(707,737	)		1.3
Balance, December 31, 2013	16,538,118			$	1.21
The weighted average exercise price was $1.33 for the 496,012 options which expired during the year ended December 31, 2013, $1.83 for the 207,498 options which expired during the year ended December 31, 2012 and $2.08 for the 100,000 options which expired during the year ended December 31, 2011.
The weighted average grant date fair value per share was $0.44, $0.47 and $0.90 for options granted during the years ended December 31, 2013, 2012 and 2011, respectively.
The Company received $1.6 million, $0 and $16,000 in proceeds from the exercise of stock options during the years ended December 31, 2013, 2012 and 2011, respectively. The aggregate intrinsic value of options exercised was $2.5 million, $0 and $65,000 during the years ended December 31, 2013, 2012 and 2011, respectively.

Commitments

Commitments	12 Months Ended
	Dec. 31, 2013
Commitments and Contingencies Disclosure [Abstract]	'
Commitments	'
	Commitments
	The Company’s corporate headquarters is located at 1787 Sentry Parkway West in Blue Bell, Pennsylvania. The lease was amended in February 2012 and runs through June 30, 2017 for a total of approximately 8,761 square feet. At the end of the lease term, the Company has the option of renewing this lease for an additional three-year lease term at an annual rate equal to the fair market rental value of the property, as defined in the lease agreement.
	The Company's corporate office in San Diego is located at 10480 Wateridge Circle in San Diego, California. This lease was signed in April 2013 and the building was occupied in early December 2013. The term of the Lease runs through December 1, 2023 and is for a total of approximately 26,500 square feet. The base rent adjusts periodically throughout the ten year term of the Lease, with monthly payments ranging from zero to $82,945. In addition, the Company will pay the landlord its share of operating expenses and a property management fee and has paid a security deposit of $64,000.
	The lease required the lessor to complete and pay for certain improvements to the building before the commencement of the lease in December 2013. The lessor completed these improvements worth approximately $2.3 million, which have been recorded as a leasehold improvement within fixed assets on the consolidated balance sheet, offset by a corresponding amount recorded in deferred rent.
	Rent expense was $906,000, $444,000, and $430,000 for the years ended December 31, 2013, 2012 and 2011, respectively. Future minimum lease payments under non-cancelable operating leases as of December 31, 2013 are as follows:
	2014	$	233,000
	2015	677,000
	2016	817,000
	2017	739,000
	2018	668,000
	Thereafter	4,620,000
	Total	$	7,754,000
	In the normal course of business, the Company is a party to a variety of agreements pursuant to which they may be obligated to indemnify the other party. It is not possible to predict the maximum potential amount of future payments under these types of agreements due to the conditional nature of our obligations and the unique facts and circumstances involved in each particular agreement. Historically, payments made by us under these types of agreements have not had a material effect on our business, consolidated results of operations or financial condition.

Investment_in_Affiliated_Entit

Investment in Affiliated Entity	12 Months Ended
	Dec. 31, 2013
Related Party Transactions [Abstract]	'
Investment in Affiliated Entity	'
	Investment in Affiliated Entity
	The Company’s investment in an affiliated entity represents the Company’s 14.7% and 16.1% ownership interest in the Korean based company, VGX Int’l, as of December 31, 2013 and 2012, respectively. This investment is measured at fair value on a recurring basis. The fair market value of the Company’s interest in VGX Int’l was determined using the closing price of VGX Int’l’s shares of common stock as listed on the Korean Stock Exchange as of December 31, 2013 and 2012.

Income_Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2013
Income Tax Disclosure [Abstract]	'
Income Taxes	'
	Income Taxes
	In accordance with the guidance pursuant to accounting for income taxes, a deferred tax asset or liability is determined based on the difference between the financial statement and tax basis of assets and liabilities as measured by the enacted tax rates which will be in effect when these differences reverse. The Company provides a valuation allowance against net deferred tax assets unless, based upon the available evidence, it is more likely than not that the deferred tax asset will be realized.
	The components of the provision for income taxes are presented in the following table:
		Year Ended December 31,
		2013			2012			2011
	Current:
	Federal	$	—		$	—		$	—
	State	(1,000		)	7,000			1,000
		$	(1,000	)	$	7,000		$	1,000
	Deferred:
	Federal	$	15,000		$	20,000		$	19,000
	State	17,000			3,000			7,000
		$	32,000		$	23,000		$	26,000
		$	31,000		$	30,000		$	27,000
	The reconciliation of income taxes attributable to operations computed at the statutory tax rates to income tax expense (recovery), using a 35% statutory tax rate, is:
		Year Ended December 31,
		2013			2012			2011
	Income (benefit) taxes at statutory rates	$	(23,118,000	)	$	(6,894,000	)	$	(5,352,000	)
	State income tax, net of federal benefit	(1,651,000		)	(1,234,000		)	(1,378,000		)
	Change in valuation allowance	8,819,000			7,415,000			7,679,000
	IRC Section 382/383 limitation	675,000			18,000			918,000
	Fair value warrant	16,129,000			(811,000		)	(3,090,000		)
	Stock compensation	279,000			603,000			(147,000		)
	Change in state tax rate	(623,000		)	438,000			125,000
	Other	(479,000		)	495,000			1,272,000
		$	31,000		$	30,000		$	27,000
	The income tax expense (recovery) has been recorded as a general and administrative expense, as its effect is immaterial.
	Significant components of the Company’s deferred tax assets and liabilities as of December 31, 2013 and 2012 are shown below:
		As of December 31,
		2013			2012
	Deferred tax assets:
	Capitalized research expense	$	2,782,000		$	3,191,000
	Net operating loss carryforwards	48,846,000			43,233,000
	Research and development and other tax credits	1,877,000			1,134,000
	Other	8,641,000			6,569,000
		62,146,000			54,127,000
	Valuation allowance	(61,061,000		)	(52,185,000		)
	Total deferred tax assets	1,085,000			1,942,000
	Deferred tax liabilities:
	Acquired intangibles	(1,096,000		)	(1,532,000		)
	Investment in affiliated entity	(123,000		)	(511,000		)
	Net deferred tax liabilities	$	(134,000	)	$	(101,000	)
	We have established a valuation allowance for all deferred tax assets including those for net operating loss (“NOL”) and tax credit carryforwards. Such a valuation allowance is recorded when it is more likely than not that the deferred tax assets will not be realized. The Company maintains a deferred tax liability related to goodwill that is not netted against the deferred tax assets, as reversal of the taxable temporary difference cannot serve as a source of income for realization of the deferred tax assets, because the deferred tax liability will not reverse until the asset is sold or written down due to impairment.
	As of December 31, 2013, the Company had federal, California and Pennsylvania tax net operating loss carry forwards of approximately $122.4 million, $38.9 million and $75.6 million, respectively, net of the net operating losses that will expire due to IRC Section 382 limitations. The federal net operating loss carry forwards will begin to expire in 2018 unless previously utilized. The California net operating loss carry forwards will begin to expire in 2014 and the Pennsylvania net operating loss carry forwards will begin to expire in 2021.
	In addition, we had federal and state research tax credit carryforwards of approximately $2.0 million net of IRS Section 382 limitation and $2.1 million, respectively. The federal tax credit carryforwards will begin to expire in 2018. The California research tax credits do not expire.
	Utilization of the NOL and tax credit carryforwards will be subject to a substantial annual limitation under Section 382 of the Internal Revenue Code of 1986, and similar state provisions due to ownership change limitations that have occurred previously or that could occur in the future. These ownership changes will limit the amount of NOL and tax credit carryforwards and other deferred tax assets that can be utilized to offset future taxable income and tax, respectively. In general, an ownership change, as defined by Section 382, results from transactions increasing ownership of certain stock holders or public groups in the stock of the corporation by more than 50 percentage points over a three-year period.
	The Company is in the process of updating the Section 382/383 study for the Company and VGX, both of which experienced ownership changes under Section 382 as a result of the Merger on June 1, 2009. Based upon the preliminary results of the study, it is estimated that approximately $28.3 million of tax benefits related to NOL and tax credit carryforwards will expire unused. Accordingly, the related NOL and R&D credit carryforwards have been removed from deferred tax assets accompanied by a corresponding reduction of the valuation allowance. Upon completion of the study, deferred tax assets relating to NOL and R&D credit carryforwards for the Company and VGX may need to be adjusted with a corresponding adjustment to the valuation allowance. Due to the existence of the valuation allowance, limitations created by current and future ownership changes, if any, related to our operations in the United States will not impact our effective tax rate. Any additional ownership changes, may further limit the ability to use the net operating losses and credits carryovers.
	The following table summarizes the activity related to our unrecognized tax benefits:
		Year ended December 31,
		2013			2012			2011
	Balance at beginning of the year	$	1,896,000		$	1,829,000		$	629,000
	Increases related to current year tax positions	305,000			72,000			158,000
	Increases (Decreases) related to prior year tax positions	215,000			(5,000		)	1,042,000
	Balance at end of the year	$	2,416,000		$	1,896,000		$	1,829,000
	The amount of unrecognized tax benefit that, if recognized and realized would affect the effective tax rate is $2.0 million as of December 31, 2013. The Company has not recorded any interest and penalties on the unrecognized tax positions as the Company has continued to generate net operating losses after accounting for the unrecognized tax benefits. The Company does not anticipate that the total amount of unrecognized tax benefits will significantly increase or decrease within twelve months of the reporting date.
	The Company and its subsidiaries are subject to United States federal income tax as well as income tax in multiple state jurisdictions. With few exceptions, the Company is no longer subject to United States federal income tax examinations for years before 2010; state and local income tax examinations before 2009; and foreign income tax examinations before 2010. However, to the extent allowed by law, the tax authorities may have the right to examine prior periods where net operating losses were generated and carried forward, and make adjustments up to the amount of the net operating loss carryforward amount. The Company is not currently under Internal Revenue Service (“IRS”), state or local tax examination.
	On September 13, 2013, the U.S. Treasury Department released final income tax regulations on the deduction and capitalization of expenditures related to tangible property. These final regulations apply to tax years beginning on or after January 1, 2014, and may be adopted in earlier years. The Company does not intend to early adopt the tax treatment of expenditures to improve tangible property and the capitalization of inherently facilitative costs to acquire tangible property as of January 1, 2013. The tangible property regulations will require the Company to make additional tax accounting method changes as of January 1, 2014; however, management does not anticipate the impact of these changes to be material to the Company’s consolidated financial position, its results of operations or its footnote disclosures.

401k_Plan

401(k) Plan	12 Months Ended
	Dec. 31, 2013
Compensation and Retirement Disclosure [Abstract]	'
401(k) Plan	'
	401(k) Plan
	In 1995, the Company adopted a 401(k) Profit Sharing Plan (the “Plan”) covering substantially all of its employees. The defined contribution plan allows the employees to contribute a percentage of their compensation each year. The Company currently matches 50% of its employees’ contributions, up to 6% of their annual compensation. The Company’s contributions are recorded as expense in the accompanying consolidated statements of operations and totaled $196,000, $170,000 and $134,000 for the years ended December 31, 2013, 2012 and 2011, respectively.

Related_Party_Transactions

Related Party Transactions	12 Months Ended
	Dec. 31, 2013
Related Party Transaction, Due from (to) Related Party [Abstract]	'
Related Party Transactions	'
	Related Party Transactions
	VGX International Inc.
	The Company conducts transactions with its affiliated entity, VGX Int’l.
	In July 2011 the Company purchased an additional 145,000 shares of VGX Int’l at a price of approximately $0.71 per share in connection with a common stock rights offering. The rights offering, however, reduced the Company’s ownership percentage, which is approximately 14.7% as of December 31, 2013.
	On October 7, 2011, the Company entered into a Collaborative Development and License Agreement (the “Agreement”) with VGX Int’l. Under the Agreement, the Company and VGX Int’l will co-develop the Company’s SynCon ® therapeutic vaccines for hepatitis B and C infections (the “Products”). Under the terms of the Agreement, VGX Int’l will receive marketing rights for the Products in Asia, excluding Japan, and in return will fully fund IND-enabling and initial Phase I and II clinical studies with respect to the Products. The Company will receive from VGX Int’l payments based on the achievement of clinical milestones and royalties based on sales of the Products in the licensed territories, retaining all commercial rights to the Products in all other territories.
	On March 24, 2010, the Company entered into a Collaboration and License Agreement (the “VGX Int’l Agreement”) with VGX Int’l. Under the VGX Int’l Agreement, the Company granted VGX Int’l an exclusive license to Inovio’s SynCon® universal influenza vaccine delivered with electroporation to be developed in certain countries in Asia (the “Product”). As consideration for the license granted to VGX Int’l, the Company received payment of $3.0 million, and will receive research support, annual license maintenance fees and royalties on net Product sales. The Company recorded the $3.0 million as deferred revenue from affiliated entity, and will recognize it as revenue over the eight year expected period of the Company’s performance obligation. In addition, contingent upon achievement of clinical and regulatory milestones, the Company will receive development payments over the term of the VGX Int’l Agreement. The VGX Int’l Agreement also provides Inovio with exclusive rights to supply devices for clinical and commercial purposes (including single use components) to VGX Int’l for use in the Product. The term of the VGX Int’l Agreement commenced upon execution and will extend on a country by country basis until the last to expire of all Royalty Periods for the territory (as such term is defined in the VGX Int’l Agreement) for any Product in that country, unless the VGX Int’l Agreement is terminated earlier in accordance with its provisions as a result of breach, by mutual agreement, or by VGX Int’l’s right to terminate without cause upon prior written notice.
	For the years ended December 31, 2013, 2012 and 2011, the Company recognized revenue from VGX Int’l of $425,000, $577,000 and $411,000, respectively, which consisted of licensing, collaborative research and development arrangements and other fees. Operating expenses related to VGX Int’l for the years ended December 31, 2013, 2012 and 2011 include $2.3 million, $871,000 and $5.3 million, respectively, related primarily to biologics manufacturing. At December 31, 2013 and 2012 the Company had an accounts receivable balance of $0 and $36,000, respectively, from VGX Int’l and its subsidiaries. At December 31, 2013, $231,000 of prepayments made to VGX Int'l were classified as long-term other assets on the consolidated balance sheet.
	Prior to signing the Roche Agreement, the Company reacquired the rights, title and interest to hepatitis B in Asia previously licensed to VGX Int'l. As a result, the Company paid $300,000 to VGX Int'l as of December 31, 2013 based on the up-front payment received from Roche.
	OncoSec Medical Incorporated
	On March 24, 2011, the Company completed the sale of certain assets related to certain non-DNA vaccine technology and intellectual property relating to selective electrochemical tumor ablation (“SECTA”) to OncoSec Medical Incorporated, or OncoSec, pursuant to an Asset Purchase Agreement dated March 14, 2011 by and between the Company and OncoSec. The Company has received payment in full of $3.0 million from OncoSec as of December 31, 2013.
	The Company's Chairman, Dr. Avtar Dhillon, is the non-executive Chairman of OncoSec.
	On September 28, 2011, the Company signed an amended agreement with OncoSec extending the term of the second payment owed to the Company in exchange for a warrant to purchase 1,000,000 shares of common stock of OncoSec. The warrant received was a five-year warrant with an exercise price of $1.20 per share. (See Note 5 for further discussion.)
	On March 24, 2012, the Company signed a second amended agreement with OncoSec further extending the term of the payments owed to the Company in exchange for a warrant to purchase 3,000,000 shares of common stock of OncoSec. The warrant received was a five-year warrant with an exercise price of $1.00 per share. (See Note 5 for further discussion.)

Quarterly_Financial_Informatio

Quarterly Financial Information (Unaudited)	12 Months Ended
	Dec. 31, 2013
Quarterly Financial Information Disclosure [Abstract]	'
Quarterly Financial Information (Unaudited)	'
	Quarterly Financial Information (Unaudited)
	The following is a summary of the quarterly results of operations of the Company for the years ended December 31, 2013 and 2012 (unaudited):
		Quarter Ended			Quarter Ended			Quarter Ended			Quarter Ended
		December 31,			September 30,			June 30,			March 31,
		2013			2013			2013			2013
	Consolidated Statements of Operations:
	Revenue:
	Revenue under collaborative research and development arrangements	$	822,217		$	8,388,760		$	14,311		$	14,259
	Revenue under collaborative research and development arrangements with affiliated entity	106,250			106,250			106,250			106,250
	Grants and miscellaneous revenue	811,199			991,835			665,049			1,334,716
	Total revenues	1,739,666			9,486,845			785,610			1,455,225
	Operating Expenses:
	Research and development	6,404,005			5,438,405			4,411,082			5,115,112
	General and administrative	4,339,539			3,282,796			3,046,586			2,974,153
	Gain on sale of assets	(1,000,000		)	—			(1,000,000		)	—
	Total operating expenses	9,743,544			8,721,201			6,457,668			8,089,265
	Loss from operations	(8,003,878		)	765,644			(5,672,058		)	(6,634,040		)
	Interest and other income, net	8,576			46,787			37,391			39,460
	Change in fair value of common stock warrants	(6,052,965		)	(34,952,210		)	(3,199,878		)	(1,427,616		)
	(Loss) Gain from investment in affiliated entity	(1,419,536		)	3,248,926			(2,032,051		)	(836,084		)
	Net loss	(15,467,803		)	(30,890,853		)	(10,866,596		)	(8,858,280		)
	Net loss attributable to non-controlling interest	13,473			13,443			14,008			14,160
	Net loss attributable to Inovio Pharmaceuticals, Inc.	$	(15,454,330	)	$	(30,877,410	)	$	(10,852,588	)	$	(8,844,120	)
	Loss per common share—basic and diluted:
	Net loss attributable to Inovio Pharmaceuticals, Inc. stockholders	$	(0.07	)	$	(0.16	)	$	(0.06	)	$	(0.06	)
	Weighted average number of common shares—basic and diluted	208,509,676			191,956,155			179,954,816			156,155,532
		Quarter Ended			Quarter Ended			Quarter Ended			Quarter Ended
		December 31,			September 30,			June 30,			March 31,
		2012			2012			2012			2012
	Consolidated Statements of Operations:
	Revenue:
	Revenue under collaborative research and development arrangements	$	14,296		$	22,495		$	20,907		$	24,838
	Revenue under collaborative research and development arrangements with affiliated entity	142,483			222,484			106,250			106,250
	Grants and miscellaneous revenue	977,974			609,717			308,925			1,562,033
	Total revenues	1,134,753			854,696			436,082			1,693,121
	Operating Expenses:
	Research and development	4,442,841			4,972,319			4,527,086			4,042,579
	General and administrative	2,919,000			2,674,362			2,696,909			2,488,088
	Gain on sale of assets	—			(500,000		)	—			(651,000		)
	Total operating expenses	7,361,841			7,146,681			7,223,995			5,879,667
	Loss from operations	(6,227,088		)	(6,291,985		)	(6,787,913		)	(4,186,546		)
	Interest and other income, net	56,520			37,013			41,036			31,544
	Change in fair value of common stock warrants	3,049,649			(1,113,638		)	3,594,782			(3,548,173		)
	Gain (Loss) from investment in affiliated entity	2,449,615			736,121			(992,373		)	(561,544		)
	Net loss	(671,304		)	(6,632,489		)	(4,144,468		)	(8,264,719		)
	Net loss attributable to non-controlling interest	12,553			10,413			11,289			9,770
	Net loss attributable to Inovio Pharmaceuticals, Inc.	$	(658,751	)	$	(6,622,076	)	$	(4,133,179	)	$	(8,254,949	)
	Loss per common share—basic and diluted:
	Net loss attributable to Inovio Pharmaceuticals, Inc. stockholders	$	—		$	(0.05	)	$	(0.03	)	$	(0.06	)
	Weighted average number of common shares—basic and diluted	140,704,889			135,389,308			134,968,394			134,968,394

Subsequent_Events

Subsequent Events	12 Months Ended
	Dec. 31, 2013
Subsequent Events [Abstract]	'
Subsequent Events	'
	Subsequent Events
	On March 4, 2014, the Company closed an underwritten public offering of 21,810,900 shares of the Company’s common stock, including 2,844,900 shares of common stock issued pursuant to the underwriter’s exercise of its overallotment option, at the public offering price of $2.90 per share. The net proceeds, after deducting the underwriter’s discounts and commission and other estimated offering expenses, were approximately $59.2 million.
	In March 2014, the Company entered into an office lease (the "Lease") with a publicly owned real estate investment trust, located in Plymouth Meeting, Pennsylvania. The Company expects to occupy the new space commencing in the third quarter of 2014. The initial term of the Lease is 11.5 years. The Company intends to use the facility for office purposes.
	The base rent adjusts periodically throughout the 11.5 year term of the Lease, with monthly payments ranging from $0 to $58,000. In addition, the Company will pay the landlord its share of operating expenses and a property management fee and has paid a security deposit of $49,000.
	Subsequent to December 31, 2013, warrants and stock options to purchase 7,619,039 shares of common stock were exercised for total proceeds to the Company of $10.2 million.

Summary_of_Significant_Account1

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2013
Accounting Policies [Abstract]	'
Basis of Presentation	'
	Basis of Presentation
	Inovio incurred a net loss of $66.0 million for the year ended December 31, 2013. Inovio had working capital of $29.7 million and an accumulated deficit of $295.8 million as of December 31, 2013. The Company’s ability to continue its operations is dependent upon its ability to obtain additional capital in the future and achieve profitable operations. The Company expects to continue to rely on outside sources of financing to meet its capital needs and the Company may never achieve positive cash flow. These consolidated financial statements do not include any adjustments to the specific amounts and classifications of assets and liabilities, which might be necessary should Inovio be unable to continue in business. Inovio’s consolidated financial statements as of and for the year ended December 31, 2013 have been prepared on a going concern basis, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business for the foreseeable future. The Company has evaluated subsequent events after the balance sheet date through the date it issued these financial statements.
Reclassification	'
	Reclassification
	Certain reclassifications have been made to the prior year consolidated financial statements to conform to the current year presentation.
Consolidation	'
	Consolidation
	These consolidated financial statements include the accounts of Inovio Pharmaceuticals, Inc. and its subsidiaries. In conjunction with the acquisition in June 2009 of VGX Pharmaceuticals (the “Merger”), the Company acquired an 88% interest in VGX Animal Health and certain shares in VGX International, Inc. (“VGX Int'l”) (a publicly-traded company in South Korea). The Company consolidates Genetronics, Inc., VGX Pharmaceuticals and its subsidiary VGX Animal Health and records a non-controlling interest for the 9% of VGX Animal Health it does not own as of December 31, 2013 and 2012. The Company's investment in VGX Int'l, which is recorded as investment in affiliated entity within the consolidated balance sheets is accounted for at fair value on a recurring basis, with changes in fair value recorded on the consolidated statements of operations within gain (loss) on investment in affiliated entity. All intercompany accounts and transactions have been eliminated upon consolidation.
Variable Interest Entities	'
	Variable Interest Entities
	In June 2009, the FASB issued authoritative guidance that requires companies to perform a qualitative analysis to determine whether a variable interest in another entity represents a controlling financial interest in a variable interest entity. A controlling financial interest in a variable interest entity is characterized by having both the power to direct the most significant activities of the entity and the obligation to absorb losses or the right to receive benefits of the entity. This guidance also requires on-going reassessments of variable interests based on changes in facts and circumstances. This guidance became effective for fiscal years beginning after November 15, 2009. The Company adopted the provisions of the guidance in the first quarter of 2010 and determined that none of the entities with which the Company currently conducts business and collaborations are variable interest entities, except VGXI (a wholly-owned subsidiary of VGX Int'l). The Company determined that they are not the primary beneficiary and therefore are not required to consolidate VGXI. The Company continues to assess its variable interests and has determined that no significant changes have occurred as of December 31, 2013.
Use of Estimates	'
	Use of Estimates
	The preparation of consolidated financial statements in accordance with United States generally accepted accounting principles requires the Company to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. Inovio bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions. On an ongoing basis, the Company reviews its estimates to ensure that these estimates appropriately reflect changes in the business or as new information becomes available.
Concentration of Credit Risk	'
	Concentration of Credit Risk
	Financial instruments, which potentially subject the Company to concentrations of credit risk, consist primarily of cash and cash equivalents, and short-term investments. The Company limits its exposure to credit loss by placing its cash and investments with high credit quality financial institutions. Additionally, the Company has established guidelines regarding diversification of its investments and their maturities which are designed to maintain principal and maximize liquidity. The Company had contracts with customers which represented more than 10% of total revenues for all of the years presented as discussed in Note 6.
Fair value of Financial Instruments	'
	Fair value of Financial Instruments
	The Company’s financial instruments consist principally of cash equivalents, short-term investments, investment in affiliated entity and common stock warrants. The carrying amounts of cash equivalents approximate the related fair values due to the short-term maturities of these instruments. Investments consist of available-for-sale securities that are reported at fair value with the related unrealized gains and losses included in accumulated other comprehensive loss, a component of consolidated stockholders’ equity. The Company’s investment in affiliated entity is accounted for at fair value on a recurring basis, with changes in fair value recorded on the consolidated statements of operations within gain(loss) from investment in affiliated entity. The estimated fair value of the common stock warrants is determined by using the Black-Scholes pricing model as of December 31, 2013, as discussed in Note 5.
Cash and Cash Equivalents	'
	Cash and Cash Equivalents
	Cash equivalents are considered by the Company to be highly liquid investments purchased with original maturities of three months or less from the date of purchase. Cash and cash equivalents include certain money market accounts at December 31, 2013 and 2012.
Restricted Cash	'
	Restricted Cash
	Restricted cash consists of a certificate of deposit with a term of 90 days which has been pledged as collateral with a financial institution. The certificate of deposit has been classified as held-to-maturity and is accounted for at amortized cost which approximates fair value. The certificate of deposit and accrued interest will automatically renew at each maturity date until termination of the agreement.
Investments	'
	Investments
	The Company defines investments as income yielding securities that can be readily converted into cash. Investments include mutual funds and municipal bonds at December 31, 2013 and certificates of deposit, mutual funds, and municipal bonds at December 31, 2012.
Accounts Receivable	'
	Accounts Receivable
	Accounts receivable are recorded at invoiced amounts and do not bear interest. Inovio performs ongoing credit evaluations of our customers’ financial condition. Credit is extended to customers as deemed necessary and generally does not require collateral. Management believes that the risk of loss is significantly reduced due to the quality and financial position of our customers.
Fixed Assets	'
	Fixed Assets
	Property and equipment are stated at cost and depreciated using the straight-line method over the estimated useful life of the assets, generally three to five years. Leasehold improvements are amortized over the shorter of the remaining term of the related leases or the estimated economic useful lives of the improvements. Repairs and maintenance are expensed as incurred.
Long-Lived Assets	'
	Long-Lived Assets
	All long-lived assets are reviewed for impairment in value when changes in circumstances dictate, based upon undiscounted future operating cash flows, and appropriate losses are recognized and reflected in current earnings, to the extent the carrying amount of an asset exceeds its estimated fair value determined by the use of appraisals, discounted cash flow analyses or comparable fair values of similar assets.
Valuation of Goodwill and Intangible Assets	'
	Valuation of Goodwill and Intangible Assets
	Goodwill represents the excess of acquisition cost over the fair value of the net assets of acquired businesses. Intangible assets are amortized over their estimated useful lives ranging from 5 to 18 years. Acquired intangible assets are continuously being developed for the future economic viability contemplated at the time of acquisition. The Company is concurrently conducting pre-clinical, Phase I, and Phase II trials using the acquired intangibles, and has entered into certain significant licensing agreements for use of these acquired intangibles.
	Historically the Company has recorded patents at cost and amortized these costs using the straight-line method over the expected useful lives of the patents or 17 years, whichever is less. Patent cost consists of the consideration paid for patents and related legal costs. Effective June 1, 2009, in connection with the acquisition of VGX, all new patent costs are being expensed as incurred. Patent cost capitalized as of June 1, 2009 will continue to be amortized over the expected life of the patent. License costs are recorded based on the fair value of consideration paid and amortized using the straight-line method over the shorter of the expected useful life of the underlying patents or the term of the related license agreement to the extent the license has an alternative future use. As of December 31, 2013 and 2012, the Company’s intangible assets resulting from the acquisition of VGX and Inovio AS, and additional intangibles including previously capitalized patent costs and license costs, net of accumulated amortization, totaled $5.7 million and $7.5 million, respectively.
	The determination of the value of such intangible assets requires management to make estimates and assumptions that affect the Company’s consolidated financial statements. The Company assesses potential impairments to intangible assets when there is evidence that events or changes in circumstances indicate that the carrying amount of an asset may not be recovered. The Company’s judgments regarding the existence of impairment indicators and future cash flows related to intangible assets are based on operational performance of our acquired businesses, market conditions and other factors. If impairment is indicated, the Company will reduce the carrying value of the intangible asset to fair value. While current and historical operating and cash flow losses are potential indicators of impairment, the Company believes the future cash flows to be received from its intangible assets will exceed the intangible assets’ carrying value, and accordingly, the Company has not recognized any impairment losses through December 31, 2013.
	Goodwill is not amortized but instead is measured for impairment annually, or when events indicate that impairment exists. The Company’s accounting policy with respect to reviewing goodwill for impairment is a two step process. The first step of the impairment test compares the fair value of our reporting unit with its carrying value including allocated goodwill. If the carrying value of the Company’s reporting unit exceeds its fair value, then the second step of the impairment test is performed to measure the impairment loss, if any. The Company tests goodwill for impairment at the entity level, which is considered our reporting unit. The Company’s estimate of fair value is determined using both the Discounted Cash Flow method of the Income Approach and the Guideline Public Company method of the Market Approach. The Discounted Cash Flow method estimates future cash flows of our business for a certain discrete period and then discounts them to their present value. The Guideline Public Company method computes value indicators (“multiples”) from the operating data of the selected publicly traded guideline companies. After these multiples were evaluated, appropriate value indicators were selected and applied to the operating statistics of the reporting unit to arrive at indications of value. Specifically, the Company relied upon the application of Total Invested Capital based valuation multiples for each guideline company. In applying the Income and Market Approaches, premiums and discounts were determined and applied to estimate the fair values of the reporting unit. To arrive at the indicated value of equity under each approach, the Company then assigned a relative weighting to the resulting values from each approach to determine whether the carrying value of the reporting unit exceeds its fair value, thus requiring step two of the impairment test.
	The Company conducts the impairment test annually on November 30th for each fiscal year for which goodwill is evaluated for impairment. The Company is also aware of the requirement to evaluate goodwill for impairment at other times should circumstances arise. To date, the Company has concluded that the fair value of the reporting unit exceeded the carrying value and therefore, step two of the impairment test has never been performed.
	Although there are inherent uncertainties in this assessment process, the estimates and assumptions the Company is using are consistent with its internal planning. If these estimates or their related assumptions change in the future, the Company may be required to record an impairment charge on all or a portion of our goodwill and intangible assets. Furthermore, the Company cannot predict the occurrence of future impairment triggering events nor the impact such events might have on its reported asset values. Future events could cause the Company to conclude that impairment indicators exist and that goodwill or other intangible assets associated with its acquired businesses are impaired. Any resulting impairment loss could have an adverse impact on the Company’s results of operations. See Note 8 for further discussion of the Company’s goodwill and intangible assets.
Income Taxes	'
	Income Taxes
	The Company recognizes deferred tax assets and liabilities for temporary differences between the financial reporting basis and the tax basis of the Company’s assets and liabilities along with net operating loss and tax credit carry forwards. The Company records a valuation allowance against its deferred tax assets to reduce the net carrying value to an amount that it believes is more likely than not to be realized. When the Company establishes or reduces the valuation allowance against its deferred tax assets, its provision for income taxes will increase or decrease, respectively, in the period such determination is made.
	Valuation allowances against the Company’s deferred tax assets were $61.1 million and $52.2 million at December 31, 2013 and 2012, respectively. Changes in the valuation allowances, when they are recognized in the provision for income taxes, are included as a component of the estimated annual effective tax rate.
Revenue Recognition	'
	Revenue Recognition
	Grant revenue
	Inovio receives non-refundable grants under available government programs. Government grants towards current expenditures are recorded as revenue when there is reasonable assurance that we have complied with all conditions necessary to receive the grants, collectability is reasonably assured, and as the expenditures are incurred.
	License fee and milestone revenue
	Inovio has adopted a strategy of co-developing or licensing its gene delivery technology for specific genes or specific medical indications. Accordingly, the Company has entered into collaborative research and development agreements and has received funding for pre-clinical research and clinical trials. Prior to the adoption of the Financial Accounting Standards Board's (“FASB”) Accounting Standards Update (“ASU”) No. 2009-13, Revenue Recognition (Topic 605): Multiple-Deliverable Revenue Arrangements, the Company analyzed its multiple element arrangements to determine whether the identified deliverables could be accounted for individually as separate units of accounting. The delivered item(s) were considered a separate unit of accounting if all of the following criteria were met: (1)the delivered item(s) has value to the customer on a standalone basis; (2)there is objective and reliable evidence of the fair value of the undelivered item(s); and (3) if the arrangement includes a general right of return relative to the delivered item, delivery or performance of the undelivered item(s) is considered probable and substantially in our control. If these criteria were not met, the deliverable was combined with other deliverables in the arrangement and accounted for as a combined unit of accounting.
	For new collaborative agreements or material modifications of existing collaborative agreements entered into after December 31, 2010, Inovio follows the provisions of ASU No. 2009-13. In order to account for the multiple-element arrangements, the Company identifies the deliverables included within the agreement and evaluates which deliverables represent separable units of accounting. Analyzing the arrangement to identify deliverables requires the use of judgment, and each deliverable may be an obligation to deliver services, a right or license to use an asset, or another performance obligation. A delivered item is considered a separate unit of accounting when the delivered item has value to the collaborator on a standalone basis based on the consideration of the relevant facts and circumstances for each arrangement.
	Arrangement consideration is allocated at the inception of the agreement to all identified units of accounting based on their relative selling price. The relative selling price for each deliverable is determined using vendor specific objective evidence (“VSOE”), of selling price or third-party evidence of selling price if VSOE does not exist. If neither VSOE nor third-party evidence of selling price exists, we use our best estimate of the selling price for the deliverable. The amount of allocable arrangement consideration is limited to amounts that are fixed or determinable. The consideration received is allocated among the separate units of accounting, and the applicable revenue recognition criteria are applied to each of the separate units. Changes in the allocation of the sales price between delivered and undelivered elements can impact revenue recognition but do not change the total revenue recognized under any agreement.
	Upfront license fee payments are recognized upon delivery of the license if facts and circumstances dictate that the license has standalone value from the undelivered items, the relative selling price allocation of the license is equal to or exceeds the upfront license fee, persuasive evidence of an arrangement exists, our price to the collaborator is fixed or determinable, and collectability is reasonably assured. Upfront license fee payments are deferred if facts and circumstances dictate that the license does not have standalone value. The determination of the length of the period over which to defer revenue is subject to judgment and estimation and can have an impact on the amount of revenue recognized in a given period.
	Prior to the adoption of ASU No. 2010-17, Revenue Recognition (Topic 605): Milestone Method of Revenue Recognition (“Milestone Method”), Inovio recognized non-refundable milestone payments upon the achievement of specified milestones upon which we had earned the milestone payment, provided the milestone payment was substantive in nature and the achievement of the milestone was not reasonably assured at the inception of the agreement. The Company deferred payments for milestone events that were reasonably assured and recognized them ratably over the minimum remaining period of our performance obligations. Payments for milestones that were not reasonably assured were treated as the culmination of a separate earnings process and were recognized as revenue when the milestones were achieved.
	Effective January 1, 2011, the Company adopted on a prospective basis the Milestone Method of ASU No. 2010-17. Under the Milestone Method, the Company will recognize consideration that is contingent upon the achievement of a milestone in its entirety as revenue in the period in which the milestone is achieved only if the milestone is substantive in its entirety. A milestone is considered substantive when it meets all of the following criteria:
	1	The consideration is commensurate with either the entity's performance to achieve the milestone or the enhancement of the value of the delivered item(s) as a result of a specific outcome resulting from the entity's performance to achieve the milestone,
	2	The consideration relates solely to past performance, and
	3	The consideration is reasonable relative to all of the deliverables and payment terms within the arrangement.
	A milestone is defined as an event (i) that can only be achieved based in whole or in part on either the entity's performance or on the occurrence of a specific outcome resulting from the entity's performance, (ii) for which there is substantive uncertainty at the date the arrangement is entered into that the event will be achieved and (iii) that would result in additional payments being due to the Company.
Research and Development Expenses	'
	Research and Development Expenses
	Since Inovio’s inception, virtually all of the Company’s activities have consisted of research and development efforts related to developing electroporation technologies and DNA vaccines. Research and development expenses consist of expenses incurred in performing research and development activities including salaries and benefits, facilities and other overhead expenses, clinical trials, contract services and other outside expenses. Research and development expenses are charged to operations as they are incurred.
Net Loss Per Share	'
	Net Loss Per Share
	Basic net loss per share is computed by dividing the net loss for the year by the weighted average number of common shares outstanding during the year. Diluted loss per share is calculated in accordance with the treasury stock method and reflects the potential dilution that would occur if securities or other contracts to issue common stock were exercised or converted to common stock. Since the effect of the assumed exercise of common stock options, warrants and other convertible securities was anti-dilutive for all periods presented, basic and diluted loss per share are the same.
Leases	'
	Leases
	Leases are classified as either capital or operating leases. Leases which transfer substantially all of the benefits and risks incidental to the ownership of assets are accounted for as if there was an acquisition of an asset and incurrence of an obligation at the inception of the lease. All other leases are accounted for as operating leases. Inovio’s Blue Bell, PA headquarters and San Diego, CA facility leases, which have escalating payments, are both expensed on a straight-line basis over the term of the lease. The allowance provided by the lessor for leasehold improvements are considered tenant incentives and are amortized on a straight-line basis over the term of the lease. These leases represent the primary expense and commitment as indicated in Note 11 “Commitments” below. Other leases exist for office machinery, such as copiers, wherein lease expense is recorded as incurred.
Stock-Based Compensation	'
	Stock-Based Compensation
	The Company recognizes compensation expense for all share-based awards made to employees, directors, and non-employees. Inovio estimates the fair value of stock options granted using the Black-Scholes option pricing model. The Black-Scholes option pricing model was developed for use in estimating the fair value of traded options, which have no vesting restrictions and are fully transferable. In addition, option valuation models require the input of highly subjective assumptions, including the expected stock price volatility and expected option life. Inovio measures the fair value of employee and director awards at the date of grant. For non-employee awards, Inovio measures the fair value at each reporting period. All option grants are amortized over the requisite service period of the awards on a straight-line basis. Expected volatility is based on historical volatility. The expected life of options granted is based on historical expected life. The risk-free interest rate is based on the United States Treasury yield in effect at the time of grant with maturities appropriate for the expected term of the stock option. The forfeiture rate is based on historical data and Inovio records stock-based compensation expense only for those awards that are expected to vest. The dividend yield is based on the fact that no dividends have been paid on common stock historically, and none are currently expected to be paid.
	Weighted average assumptions used in the Black-Scholes model for employees and directors are presented below:
		Year Ended December 31,
		2013	2012	2011
	Risk-free interest rate	0.41%	0.36%	1.23%
	Expected volatility	111%	131%	134%
	Expected life in years	4	4	4
	Dividend yield	—	—	—
	Forfeiture rate	8%	8%	11%
	Assumptions used in the Black-Scholes model for non-employees are presented below:
		Year Ended December 31,
		2013	2012	2011
	Risk-free interest rate	0.84% – 1.52%	0.67% – 0.83%	0.91% – 3.47%
	Expected volatility	102%-113%	103%-117%	96%-119%
	Expected life in years	10-Jul	10-Jul	10-Jun
	Dividend yield	—	—	—
Recent Accounting Pronouncements	'
	Recent Accounting Pronouncements
	The below recent pronouncement may have a significant effect on the Company's financial statements. Recent pronouncements that are not anticipated to have an impact on or are unrelated to the Company's financial condition, results of operations, or related disclosures are not discussed.
	Accounting Standards Update (“ASU”), No. 2013-02-In February 2013, the Financial Accounting Standards Board (“FASB”) issued an ASU which amended the disclosure requirements regarding the reporting of amounts reclassified out of accumulated other comprehensive income. The amendment does not change the current requirement for reporting net income or other comprehensive income, but requires additional disclosures about significant amounts reclassified out of accumulated other comprehensive income including the effect of the reclassification on the related net income line items. The Company has adopted ASU 2013-02 prospectively effective January 1, 2013 and the adoption is not expected to have a significant impact on the Company's financial statements as the requirements are disclosure only in nature.

Summary_of_Significant_Account2

Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2013
Accounting Policies [Abstract]	'
Summary of common shares that were excluded from the diluted net loss per share calculation because of their anti-dilutive effect	'
	The following table summarizes potential common shares that were excluded from diluted net loss per share calculation because of their anti-dilutive effect:
		Year Ended December 31,
		2013		2012		2011
	Options to purchase common stock	16,538,118		16,257,444		14,302,803
	Warrants to purchase common stock	14,059,260		21,593,844		21,743,844
	Convertible preferred stock	38,233		38,233		38,233
	Total	30,635,611		37,889,521		36,084,880
Summary of assumptions used to estimate the fair value of stock options	'
	Weighted average assumptions used in the Black-Scholes model for employees and directors are presented below:
		Year Ended December 31,
		2013	2012		2011
	Risk-free interest rate	0.41%	0.36%		1.23%
	Expected volatility	111%	131%		134%
	Expected life in years	4	4		4
	Dividend yield	—	—		—
	Forfeiture rate	8%	8%		11%
	Assumptions used in the Black-Scholes model for non-employees are presented below:
		Year Ended December 31,
		2013	2012		2011
	Risk-free interest rate	0.84% – 1.52%	0.67% – 0.83%		0.91% – 3.47%
	Expected volatility	102%-113%	103%-117%		96%-119%
	Expected life in years	10-Jul	10-Jul		10-Jun
	Dividend yield	—	—		—

Investments_Tables

Investments (Tables)	12 Months Ended
	Dec. 31, 2013
Investments, Debt and Equity Securities [Abstract]	'
Summary of investments	'
	The following is a summary of short-tem investments as of December 31, 2013 and 2012:
			As of December 31, 2013
		Contractual	Cost		Gross Unrealized		Gross Unrealized			Fair Market Value
		Maturity (in years)			Gains		Losses
	Mutual funds	---	$	18,178,518	$	—	$	(78,614	)	$	18,099,904
	Municipal bonds	Less than 1	805,144		560		—			805,704
	Total investments		$	18,983,662	$	560	$	(78,614	)	$	18,905,608
			As of December 31, 2012
		Contractual	Cost		Gross Unrealized		Gross Unrealized			Fair Market Value
		Maturity (in years)			Gains		Losses
	Mutual funds	---	$	7,500,063	$	83,868	$	—		$	7,583,931
	Certificates of deposit	Less than 1	250,000		—		—			250,000
	Municipal bonds	Less than 1	201,470		—		(1,400		)	200,070
	Total investments		$	7,951,533	$	83,868	$	(1,400	)	$	8,034,001

Fair_Value_Measurements_Tables

Fair Value Measurements (Tables)	12 Months Ended
	Dec. 31, 2013
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'
Financial assets and liabilities measured at fair value on a recurring basis	'
	The following table presents the Company’s assets and liabilities that are measured at fair value on a recurring basis as of December 31, 2013:
		Fair Value Measurements at
		December 31, 2013
		Total			Using Quoted Prices			Using Significant		Using Significant
					in Active Markets			Other Unobservable		Unobservable
					for Identical Assets			Inputs		Inputs
					(Level 1)			(Level 2)		(Level 3)
	Assets:
	Money market funds	$	26,852,560		$	26,852,560				$	—
	Mutual funds	18,099,904			—			18,099,904		—
	Municipal bonds	805,704			—			805,704		—
	Investment in affiliated entity	9,664,587			9,664,587			—		—
	Common stock warrants	717,500			—			—		717,500
	Total Assets	$	56,140,255		$	36,517,147		$	18,905,608	$	717,500
	Liabilities:
	Common stock warrants	$	19,540,583		$	—		$	—	$	19,540,583
	Total Liabilities	$	19,540,583		$	—		$	—	$	19,540,583
	The following table presents the Company’s assets and liabilities that are measured at fair value on a recurring basis as of December 31, 2012:
		Fair Value Measurements at
		December 31, 2012
		Total			Using Quoted Prices			Using Significant		Using Significant
					in Active Markets			Other Unobservable		Unobservable
					for Identical Assets			Inputs		Inputs
					(Level 1)			(Level 2)		(Level 3)
	Assets:
	Money market funds	$	1,686,406		$	1,686,406		$	—	$	—
	Mutual funds	7,583,931			—			7,583,931		—
	Certificates of deposit	250,000			—			250,000		—
	Municipal bonds	200,070			—			200,070		—
	Investment in affiliated entity	10,703,332			10,703,332			—		—
	Common stock warrants	267,200			—			—		267,200
	Total Assets	$	20,690,939		$	12,389,738		$	8,034,001	$	267,200
	Liabilities:
	Common stock warrants	$	2,859,899		$	—		$	—	$	2,859,899
	Total Liabilities	$	2,859,899		$	—		$	—	$	2,859,899
Assumptions used to estimate the fair values of the common stock warrants	'
	The range of assumptions used to estimate the fair values of common stock warrants at December 31, 2013 are presented below:
	Risk-free interest rate	0.13%-1.75%
	Expected volatility	90%-112%
	Expected life in years	.50-4.70
	Dividend yield	—
Change in fair value of the financial assets	'
	The following table presents a summary of changes in fair value of the Company’s total Level 3 financial assets for the years ended December 31, 2013 and 2012:
		Year Ended			Year Ended
		December 31, 2013			December 31, 2012
	Balance at beginning of year	$	267,200		$	100,000
	Common stock warrant recorded at fair value upon acquisition	—			501,000
	Increase (Decrease) in fair value included in change in fair value of common stock warrants	450,300			(333,800		)
	Balance at end of year	$	717,500		$	267,200
Changes in fair value of the financial liabilities	'
	The following table presents the changes in fair value of the Company’s total Level 3 financial liabilities for the years ended December 31, 2013 and 2012:
		Year Ended			Year Ended
		December 31,			December 31,
		2013			2012
	Balance at beginning of year	$	2,859,899		$	5,176,319
	Record fair value of warrants issued in March 2013 financing	5,968,244			—
	Increase (Decrease) in fair value included in change in fair value of common stock warrants	46,082,969			(2,316,420		)
	Change in classification from liability to stockholders' equity due to warrant exercises	(35,370,529		)	—
	Balance at end of year	$	19,540,583		$	2,859,899
OncoSec [Member]	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'
Assumptions used to estimate the fair values of the common stock warrants	'
	The assumptions used to estimate the fair values of the OncoSec common stock warrants at December 31, 2013 are presented below:
	Risk-free interest rate	0.78%
	Expected volatility	85%
	Expected life in years	2.75-3.25
	Dividend yield	—

Major_Customers_and_Concentrat1

Major Customers and Concentration of Credit Risk (Tables)	12 Months Ended
	Dec. 31, 2013
Risks and Uncertainties [Abstract]	'
Schedule of major customers and concentration risks	'
	Customer	2013		% of Total		2012		% of Total		2011		% of Total
				Revenue				Revenue				Revenue
	Roche	$	9,181,759	68	%	$	—	—	%	$	—	—	%
	NIAID	2,090,939		16		2,831,115		69	%	7,801,976		80	%
	VGX Int'l (affiliated entity)	425,000		3		577,467		14		411,459		4
	All other	1,769,648		13		710,070		17		1,581,822		16
	Total Revenue	$	13,467,346	100	%	$	4,118,652	100	%	$	9,795,257	100	%

Fixed_Assets_Tables

Fixed Assets (Tables)	12 Months Ended
	Dec. 31, 2013
Property, Plant and Equipment [Abstract]	'
Schedule of fixed assets	'
	Fixed assets at December 31, 2013 and 2012 consist of the following:
		Cost		Accumulated			Net Book
				Depreciation			Value
				and
				Amortization
	As of December 31, 2013
	Machinery, equipment and office furniture	$	2,381,033	$	(1,807,706	)	$	573,327
	Leasehold improvements	2,420,940		(107,722		)	2,313,218
		$	4,801,973	$	(1,915,428	)	$	2,886,545
	As of December 31, 2012
	Machinery, equipment and office furniture	$	2,014,588	$	(1,731,660	)	$	282,928
	Leasehold improvements	466,135		(386,042		)	80,093
		$	2,480,723	$	(2,117,702	)	$	363,021

Goodwill_and_Intangible_Assets1

Goodwill and Intangible Assets (Tables)	12 Months Ended
	Dec. 31, 2013
Goodwill and Intangible Assets Disclosure [Abstract]	'
Summary of intangible assets by major asset class	'
	The following sets forth the goodwill and intangible assets by major asset class:
				December 31, 2013							December 31, 2012
		Useful		Gross		Accumulated			Net Book		Gross		Accumulated			Net Book
		Life				Amortization			Value				Amortization			Value
		(Yrs)
	Non-Amortizing:
	Goodwill(a)			$	10,113,371	$	—		$	10,113,371	$	10,113,371	$	—		$	10,113,371
	Amortizing:
	Patents	8 – 17		5,802,528		(5,128,227		)	674,301		5,802,528		(4,852,673		)	949,855
	Licenses	8 – 17		1,323,761		(1,075,617		)	248,144		1,323,761		(1,046,870		)	276,891
	CELLECTRA®(b)	5 – 11		8,106,270		(5,543,786		)	2,562,484		8,106,270		(4,334,234		)	3,772,036
	GHRH(b)	11		335,314		(145,215		)	190,099		335,314		(113,531		)	221,783
	Other(c)	18		4,050,000		(2,006,250		)	2,043,750		4,050,000		(1,781,250		)	2,268,750
	Total intangible assets			19,617,873		(13,899,095		)	5,718,778		19,617,873		(12,128,558		)	7,489,315
	Total goodwill and intangible assets			$	29,731,244	$	(13,899,095	)	$	15,832,149	$	29,731,244	$	(12,128,558	)	$	17,602,686
	(a)	Goodwill was recorded from the Inovio AS acquisition in January 2005 and from the acquisition of VGX in June 2009 for $3.9 million and $6.2 million, respectively.
	(b)	CELLECTRA® and GHRH are developed technologies which were recorded from the acquisition of VGX.
	(c)	Other intangible assets represent the fair value of acquired intellectual property from the Inovio AS acquisition.
Schedule of finite-lived intangible assets, future amortization expense	'
	Amortization expense related to intangible assets at December 31, 2013 for each of the next five fiscal years and beyond is expected to be incurred as follows:
	2014	$	943,000
	2015	870,000
	2016	816,000
	2017	775,000
	2018	773,000
	Thereafter	1,542,000
		$	5,719,000

Accounts_Payable_and_Accrued_E1

Accounts Payable and Accrued Expenses (Tables)	12 Months Ended
	Dec. 31, 2013
Payables and Accruals [Abstract]	'
Schedule of accounts payable and accrued expenses	'
	Accounts payable and accrued expenses at December 31, 2013 and 2012 consist of the following:
		As of		As of
		December 31,		December 31,
		2013		2012
	Trade accounts payable	$	1,865,723	$	852,573
	Accrued compensation	2,586,806		1,560,704
	Other accrued expenses	991,979		768,297
		$	5,444,508	$	3,181,574

Stockholders_Equity_Tables

Stockholders' Equity (Tables)	12 Months Ended
	Dec. 31, 2013
Stockholders' Equity Note [Abstract]	'
Summary of preferred stock authorized, issued and outstanding	'
								Outstanding
								as of
								December 31,
		Authorized			Issued			2013		2012
	Series A Preferred Stock, par $0.001	1,000			817			—		—
	Series B Preferred Stock, par $0.001	1,000			750			—		—
	Series C Preferred Stock, par $0.001	1,091			1,091			26		26
	Series D Preferred Stock, par $0.001	1,966,292			1,966,292			—		—
Summary of warrants outstanding	'
	The following table summarizes the warrants outstanding as of December 31, 2013 and 2012:
									As of December 31, 2013					As of December 31, 2012
	Issued in Connection With:		Exercise				Expiration		Number of		Common Stock			Number of	Common Stock
			Price				Date		Warrants		Warrant Liability			Warrants	Warrant Liability
	March 2013 financing		$	0.79			September 12, 2018		3,022,725		$	7,859,085		—	$	—
	December 2011 financing		$	0.65			6-Dec-16		—		—			5,774,784	2,078,921
	January 2011 financing		$	1.4			January 27, 2016		6,695,000		11,381,498			10,565,200	779,711
	July 2009 financing		$	3.38			1-Jul-14		333,333		300,000			333,333	1,267
	Warrants assumed in June 2009 Merger		$1.02-$1.28				August 1, 2015-		4,008,202		—			4,920,527	—
							28-Apr-16
	Total								14,059,260		$	19,540,583		21,593,844	$	2,859,899
Schedule of shares authorized under stock option plans, by exercise price range	'
	The following table summarizes total stock options outstanding at December 31, 2013:
			Options Outstanding								Options Exercisable
	Exercise Price		Options			Weighted-Average		Weighted			Options		Weighted-Average
			Outstanding			Remaining		Average			Exercisable		Exercise Price
						Contractual Life		Exercise Price
						(in Years)
	$0.00 – $1.00		5,888,591			8.2		$	0.56		2,561,431		$	0.57
	$1.01 – $2.00		9,363,064			4.1		$	1.32		8,903,626		$	1.32
	$2.01 – $4.00		1,047,713			3.1		$	3.02		986,307		$	3.06
	$4.01 – $6.00		188,750			0.3		$	4.86		188,750		$	4.86
	$6.01 – $6.12		50,000			0.2		$	6.12		50,000		$	6.12
			16,538,118			5.5		$	1.21		12,690,114		$	1.38
Schedule of stock options, activity	'
	Stock option activity under our stock option plans was as follows:
		Number of			Weighted-Average
		Shares			Exercise Price
	Balance, December 31, 2010	12,649,968			$	1.49
	Granted	2,068,750			1.1
	Exercised	(68,309	)		0.23
	Cancelled	(347,606	)		2.25
	Balance, December 31, 2011	14,302,803			1.42
	Granted	2,733,750			0.58
	Exercised	—			—
	Cancelled	(779,109	)		1.55
	Balance, December 31, 2012	16,257,444			1.28
	Granted	2,913,625			0.61
	Exercised	(1,925,214	)		0.81
	Cancelled	(707,737	)		1.3
	Balance, December 31, 2013	16,538,118			$	1.21

Commitments_Tables

Commitments (Tables)	12 Months Ended
	Dec. 31, 2013
Commitments and Contingencies Disclosure [Abstract]	'
Schedule of Future minimum lease payments under non-cancelable operating leases	'
	Future minimum lease payments under non-cancelable operating leases as of December 31, 2013 are as follows:
	2014	$	233,000
	2015	677,000
	2016	817,000
	2017	739,000
	2018	668,000
	Thereafter	4,620,000
	Total	$	7,754,000

Income_Taxes_Tables

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2013
Income Tax Disclosure [Abstract]	'
Schedule of components of income tax expense (benefit)	'
	The components of the provision for income taxes are presented in the following table:
		Year Ended December 31,
		2013			2012			2011
	Current:
	Federal	$	—		$	—		$	—
	State	(1,000		)	7,000			1,000
		$	(1,000	)	$	7,000		$	1,000
	Deferred:
	Federal	$	15,000		$	20,000		$	19,000
	State	17,000			3,000			7,000
		$	32,000		$	23,000		$	26,000
		$	31,000		$	30,000		$	27,000
Schedule of effective income tax rate reconciliation	'
	The reconciliation of income taxes attributable to operations computed at the statutory tax rates to income tax expense (recovery), using a 35% statutory tax rate, is:
		Year Ended December 31,
		2013			2012			2011
	Income (benefit) taxes at statutory rates	$	(23,118,000	)	$	(6,894,000	)	$	(5,352,000	)
	State income tax, net of federal benefit	(1,651,000		)	(1,234,000		)	(1,378,000		)
	Change in valuation allowance	8,819,000			7,415,000			7,679,000
	IRC Section 382/383 limitation	675,000			18,000			918,000
	Fair value warrant	16,129,000			(811,000		)	(3,090,000		)
	Stock compensation	279,000			603,000			(147,000		)
	Change in state tax rate	(623,000		)	438,000			125,000
	Other	(479,000		)	495,000			1,272,000
		$	31,000		$	30,000		$	27,000
Schedule of deferred tax assets and liabilities	'
	Significant components of the Company’s deferred tax assets and liabilities as of December 31, 2013 and 2012 are shown below:
		As of December 31,
		2013			2012
	Deferred tax assets:
	Capitalized research expense	$	2,782,000		$	3,191,000
	Net operating loss carryforwards	48,846,000			43,233,000
	Research and development and other tax credits	1,877,000			1,134,000
	Other	8,641,000			6,569,000
		62,146,000			54,127,000
	Valuation allowance	(61,061,000		)	(52,185,000		)
	Total deferred tax assets	1,085,000			1,942,000
	Deferred tax liabilities:
	Acquired intangibles	(1,096,000		)	(1,532,000		)
	Investment in affiliated entity	(123,000		)	(511,000		)
	Net deferred tax liabilities	$	(134,000	)	$	(101,000	)
Schedule of unrecognized tax benefits rollforward	'
	The following table summarizes the activity related to our unrecognized tax benefits:
		Year ended December 31,
		2013			2012			2011
	Balance at beginning of the year	$	1,896,000		$	1,829,000		$	629,000
	Increases related to current year tax positions	305,000			72,000			158,000
	Increases (Decreases) related to prior year tax positions	215,000			(5,000		)	1,042,000
	Balance at end of the year	$	2,416,000		$	1,896,000		$	1,829,000

Quarterly_Financial_Informatio1

Quarterly Financial Information (Unaudited) (Tables)	12 Months Ended
	Dec. 31, 2013
Quarterly Financial Information Disclosure [Abstract]	'
Schedule of quarterly financial information (unaudited)	'
	The following is a summary of the quarterly results of operations of the Company for the years ended December 31, 2013 and 2012 (unaudited):
		Quarter Ended			Quarter Ended			Quarter Ended			Quarter Ended
		December 31,			September 30,			June 30,			March 31,
		2013			2013			2013			2013
	Consolidated Statements of Operations:
	Revenue:
	Revenue under collaborative research and development arrangements	$	822,217		$	8,388,760		$	14,311		$	14,259
	Revenue under collaborative research and development arrangements with affiliated entity	106,250			106,250			106,250			106,250
	Grants and miscellaneous revenue	811,199			991,835			665,049			1,334,716
	Total revenues	1,739,666			9,486,845			785,610			1,455,225
	Operating Expenses:
	Research and development	6,404,005			5,438,405			4,411,082			5,115,112
	General and administrative	4,339,539			3,282,796			3,046,586			2,974,153
	Gain on sale of assets	(1,000,000		)	—			(1,000,000		)	—
	Total operating expenses	9,743,544			8,721,201			6,457,668			8,089,265
	Loss from operations	(8,003,878		)	765,644			(5,672,058		)	(6,634,040		)
	Interest and other income, net	8,576			46,787			37,391			39,460
	Change in fair value of common stock warrants	(6,052,965		)	(34,952,210		)	(3,199,878		)	(1,427,616		)
	(Loss) Gain from investment in affiliated entity	(1,419,536		)	3,248,926			(2,032,051		)	(836,084		)
	Net loss	(15,467,803		)	(30,890,853		)	(10,866,596		)	(8,858,280		)
	Net loss attributable to non-controlling interest	13,473			13,443			14,008			14,160
	Net loss attributable to Inovio Pharmaceuticals, Inc.	$	(15,454,330	)	$	(30,877,410	)	$	(10,852,588	)	$	(8,844,120	)
	Loss per common share—basic and diluted:
	Net loss attributable to Inovio Pharmaceuticals, Inc. stockholders	$	(0.07	)	$	(0.16	)	$	(0.06	)	$	(0.06	)
	Weighted average number of common shares—basic and diluted	208,509,676			191,956,155			179,954,816			156,155,532
		Quarter Ended			Quarter Ended			Quarter Ended			Quarter Ended
		December 31,			September 30,			June 30,			March 31,
		2012			2012			2012			2012
	Consolidated Statements of Operations:
	Revenue:
	Revenue under collaborative research and development arrangements	$	14,296		$	22,495		$	20,907		$	24,838
	Revenue under collaborative research and development arrangements with affiliated entity	142,483			222,484			106,250			106,250
	Grants and miscellaneous revenue	977,974			609,717			308,925			1,562,033
	Total revenues	1,134,753			854,696			436,082			1,693,121
	Operating Expenses:
	Research and development	4,442,841			4,972,319			4,527,086			4,042,579
	General and administrative	2,919,000			2,674,362			2,696,909			2,488,088
	Gain on sale of assets	—			(500,000		)	—			(651,000		)
	Total operating expenses	7,361,841			7,146,681			7,223,995			5,879,667
	Loss from operations	(6,227,088		)	(6,291,985		)	(6,787,913		)	(4,186,546		)
	Interest and other income, net	56,520			37,013			41,036			31,544
	Change in fair value of common stock warrants	3,049,649			(1,113,638		)	3,594,782			(3,548,173		)
	Gain (Loss) from investment in affiliated entity	2,449,615			736,121			(992,373		)	(561,544		)
	Net loss	(671,304		)	(6,632,489		)	(4,144,468		)	(8,264,719		)
	Net loss attributable to non-controlling interest	12,553			10,413			11,289			9,770
	Net loss attributable to Inovio Pharmaceuticals, Inc.	$	(658,751	)	$	(6,622,076	)	$	(4,133,179	)	$	(8,254,949	)
	Loss per common share—basic and diluted:
	Net loss attributable to Inovio Pharmaceuticals, Inc. stockholders	$	—		$	(0.05	)	$	(0.03	)	$	(0.06	)
	Weighted average number of common shares—basic and diluted	140,704,889			135,389,308			134,968,394			134,968,394

Summary_of_Significant_Account3

Summary of Significant Accounting Policies (Details) (USD $)	3 Months Ended								12 Months Ended
	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2012	Sep. 30, 2012	Jun. 30, 2012	Mar. 31, 2012	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Basis of Presentation [Abstract]	'	'	'	'	'	'	'	'	'	'	'
Net loss from operations	($15,454,330)	($30,877,410)	($10,852,588)	($8,844,120)	($658,751)	($6,622,076)	($4,133,179)	($8,254,949)	($66,028,448)	($19,668,955)	($15,252,945)
Working capital	29,700,000	'	'	'	'	'	'	'	29,700,000	'	'
Accumulated deficit	-295,788,577	'	'	'	-229,760,129	'	'	'	-295,788,577	-229,760,129	'
Consolidation [Abstract]	'	'	'	'	'	'	'	'	'	'	'
Interest in VGX Animal Health	88.00%	'	'	'	'	'	'	'	88.00%	'	'
Non-controlling interest	9.00%	'	'	'	9.00%	'	'	'	9.00%	9.00%	'
Accounts Receivable [Abstract]	'	'	'	'	'	'	'	'	'	'	'
Allowance for doubtful accounts	0	'	'	'	0	'	'	'	0	0	'
Income Taxes [Abstract]	'	'	'	'	'	'	'	'	'	'	'
Deferred tax assets, valuation allowance	$61,061,000	'	'	'	$52,185,000	'	'	'	$61,061,000	$52,185,000	'

Summary_of_Significant_Account4

Summary of Significant Accounting Policies - Fixed Assets (Details)	12 Months Ended
	Dec. 31, 2013
Minimum [Member]	'
Property, Plant and Equipment [Line Items]	'
Property and equipment estimated useful life	'3 years
Maximum [Member]	'
Property, Plant and Equipment [Line Items]	'
Property and equipment estimated useful life	'5 years

Summary_of_Significant_Account5

Summary of Significant Accounting Policies - Valuation of Goodwill and Intangible Assets (Details) (USD $)	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013	Dec. 31, 2013	Dec. 31, 2013	Dec. 31, 2013
			Minimum [Member]	Maximum [Member]	Patents [Member]	Patents [Member]
					Minimum [Member]	Maximum [Member]
Finite-Lived Intangible Assets [Line Items]	'	'	'	'	'	'
Finite lived intangible asset, useful life	'	'	'5 years	'18 years	'8 years	'17 years
Intangible assets, net	$5,718,778	$7,489,315	'	'	'	'

Summary_of_Significant_Account6

Summary of Significant Accounting Policies - Net Loss per Share (Details)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Summary of common shares that were excluded from the diluted net loss per share calculation because of their anti-dilutive effect	'	'	'
Total	30,635,611	37,889,521	36,084,880
Options to purchase common stock [Member]	'	'	'
Summary of common shares that were excluded from the diluted net loss per share calculation because of their anti-dilutive effect	'	'	'
Total	16,538,118	16,257,444	14,302,803
Warrants to purchase common stock [Member]	'	'	'
Summary of common shares that were excluded from the diluted net loss per share calculation because of their anti-dilutive effect	'	'	'
Total	14,059,260	21,593,844	21,743,844
Convertible preferred stock [Member]	'	'	'
Summary of common shares that were excluded from the diluted net loss per share calculation because of their anti-dilutive effect	'	'	'
Total	38,233	38,233	38,233

Summary_of_Significant_Account7

Summary of Significant Accounting Policies - Stock-Based Compensation (Details) (Stock Options [Member])	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Employees and Directors [Member]	'	'	'
Summary of assumptions used to estimate the fair value of stock options	'	'	'
Risk-free interest rate	0.41%	0.36%	1.23%
Expected volatility	111.00%	131.00%	134.00%
Expected life in years	'4 years	'4 years	'4 years
Dividend yield	0.00%	0.00%	0.00%
Forfeiture rate	8.00%	8.00%	11.00%
Non Employee [Member]	'	'	'
Summary of assumptions used to estimate the fair value of stock options	'	'	'
Risk-free interest rate (minimum)	0.84%	0.67%	0.91%
Risk-free interest rate (maximum)	1.52%	0.83%	3.47%
Dividend yield	0.00%	0.00%	0.00%
Non Employee [Member] | Minimum [Member]	'	'	'
Summary of assumptions used to estimate the fair value of stock options	'	'	'
Expected volatility	102.00%	103.00%	96.00%
Expected life in years	'7 years	'7 years	'6 years
Non Employee [Member] | Maximum [Member]	'	'	'
Summary of assumptions used to estimate the fair value of stock options	'	'	'
Expected volatility	113.00%	117.00%	119.00%
Expected life in years	'10 years	'10 years	'10 years

Collaborative_Agreements_Colla

Collaborative Agreements Collaborative Agreements (Details) (USD $)

3 Months Ended

12 Months Ended

1 Months Ended

12 Months Ended

1 Months Ended

Dec. 31, 2013

Sep. 30, 2013

Jun. 30, 2013

Mar. 31, 2013

Dec. 31, 2012

Sep. 30, 2012

Jun. 30, 2012

Mar. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Sep. 30, 2013

Sep. 30, 2013

Dec. 31, 2013

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2013

Collaborative Arrangement, Product [Member]

Roche [Member]

Roche [Member]

INO 1800 [Member]

INO 5150 [Member]

Nonsoftware License Arrangement [Member]

Nonsoftware License Arrangement [Member]

Collaborative Arrangement, Product [Member]

Collaborative Arrangement, Product [Member]

Collaborative Arrangement, Product [Member]

Collaborative Arrangement, Product [Member]

Option Right [Member]

Joint Steering Committee Obligation [Member]

Collaborative Arrangement, Product [Member]

Collaborative Arrangement, Product [Member]

Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Upfront payment received

'

'

'

'

'

'

'

'

'

'

'

$10,000,000

$10,000,000

'

'

'

'

'

Anticipated development and regulatory event based payment receivable

'

'

'

'

'

'

'

'

'

'

'

'

412,500,000

'

'

'

'

'

Anticipated development and regulatory event based payment receivable milestones

'

'

'

'

'

'

'

'

'

'

'

'

3,000,000

'

'

'

'

'

Commercial event based payment received

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

Length of period after date of product first commercial sale to determine agreement in effect terms

'

'

'

'

'

'

'

'

'

'

'

'

'10 years

'

'

'

'

'

Revenue recognized

'

'

'

'

'

'

'

'

'

'

'

'

'

'

3,400,000

5,000,000

'

'

Deferred revenue, additions

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1,500,000

155,000

Revenue under collaborative research and development arrangements

822,217

8,388,760

14,311

14,259

14,296

22,495

20,907

24,838

9,239,547

82,536

156,397

'

'

9,200,000

'

'

'

'

Revenue under collaborative research and development arrangements allocated to the licenses

'

'

'

'

'

'

'

'

'

'

'

'

'

9,100,000

'

'

'

'

Revenue under collaborative research and development arrangements allocated to research and development services and manufacturing

'

'

'

'

'

'

'

'

'

'

'

'

'

84,000

'

'

'

'

Deferred revenue

'

'

'

'

'

'

'

'

'

'

'

'

'

$3,400,000

'

'

'

'

Investments_Details

Investments (Details) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Summary of investments	'	'
Cost	18,983,662	7,951,533
Gross Unrealized Gains	560	83,868
Gross Unrealized Losses	-78,614	-1,400
Fair Market Value	18,905,608	8,034,001
Mutual funds [Member]	'	'
Summary of investments	'	'
Cost	18,178,518	7,500,063
Gross Unrealized Gains	0	83,868
Gross Unrealized Losses	-78,614	0
Fair Market Value	18,099,904	7,583,931
Certificates of deposit [Member]	'	'
Summary of investments	'	'
Cost	'	250,000
Gross Unrealized Gains	'	0
Gross Unrealized Losses	'	0
Fair Market Value	'	250,000
Municipal bonds [Member]	'	'
Summary of investments	'	'
Cost	805,144	201,470
Gross Unrealized Gains	560	0
Gross Unrealized Losses	0	-1,400
Fair Market Value	805,704	200,070
Maximum [Member] | Certificates of deposit [Member]	'	'
Summary of investments	'	'
Contractual Maturity (less than 1 year)	'	'1 year
Maximum [Member] | Municipal bonds [Member]	'	'
Summary of investments	'	'
Contractual Maturity (less than 1 year)	'1 year	'1 year

Investments_Details_Textual

Investments (Details Textual) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Investments (Textual) [Abstract]	'	'	'
Investment impairment charges	$39,000	$0	$0

Fair_Value_Measurements_Detail

Fair Value Measurements (Details) (Fair Value, Measurements, Recurring [Member], USD $)	Dec. 31, 2013	Dec. 31, 2012
Financial assets and liabilities that are measured at fair value on recurring basis	'	'
Assets, fair value	$56,140,255	$20,690,939
Liabilities, fair value	19,540,583	2,859,899
Using Quoted Prices in Active Markets for Identical Assets (Level 1) [Member]	'	'
Financial assets and liabilities that are measured at fair value on recurring basis	'	'
Assets, fair value	36,517,147	12,389,738
Liabilities, fair value	0	0
Using Significant Other Unobservable Inputs (Level 2) [Member]	'	'
Financial assets and liabilities that are measured at fair value on recurring basis	'	'
Assets, fair value	18,905,608	8,034,001
Liabilities, fair value	0	0
Using Significant Unobservable Inputs (Level 3) [Member]	'	'
Financial assets and liabilities that are measured at fair value on recurring basis	'	'
Assets, fair value	717,500	267,200
Liabilities, fair value	19,540,583	2,859,899
Money market funds [Member]	'	'
Financial assets and liabilities that are measured at fair value on recurring basis	'	'
Assets, fair value	26,852,560	1,686,406
Money market funds [Member] | Using Quoted Prices in Active Markets for Identical Assets (Level 1) [Member]	'	'
Financial assets and liabilities that are measured at fair value on recurring basis	'	'
Assets, fair value	26,852,560	1,686,406
Money market funds [Member] | Using Significant Other Unobservable Inputs (Level 2) [Member]	'	'
Financial assets and liabilities that are measured at fair value on recurring basis	'	'
Assets, fair value	'	0
Money market funds [Member] | Using Significant Unobservable Inputs (Level 3) [Member]	'	'
Financial assets and liabilities that are measured at fair value on recurring basis	'	'
Assets, fair value	0	0
Mutual funds [Member]	'	'
Financial assets and liabilities that are measured at fair value on recurring basis	'	'
Assets, fair value	18,099,904	7,583,931
Mutual funds [Member] | Using Quoted Prices in Active Markets for Identical Assets (Level 1) [Member]	'	'
Financial assets and liabilities that are measured at fair value on recurring basis	'	'
Assets, fair value	0	0
Mutual funds [Member] | Using Significant Other Unobservable Inputs (Level 2) [Member]	'	'
Financial assets and liabilities that are measured at fair value on recurring basis	'	'
Assets, fair value	18,099,904	7,583,931
Mutual funds [Member] | Using Significant Unobservable Inputs (Level 3) [Member]	'	'
Financial assets and liabilities that are measured at fair value on recurring basis	'	'
Assets, fair value	0	0
Certificates of deposit [Member]	'	'
Financial assets and liabilities that are measured at fair value on recurring basis	'	'
Assets, fair value	'	250,000
Certificates of deposit [Member] | Using Quoted Prices in Active Markets for Identical Assets (Level 1) [Member]	'	'
Financial assets and liabilities that are measured at fair value on recurring basis	'	'
Assets, fair value	'	0
Certificates of deposit [Member] | Using Significant Other Unobservable Inputs (Level 2) [Member]	'	'
Financial assets and liabilities that are measured at fair value on recurring basis	'	'
Assets, fair value	'	250,000
Certificates of deposit [Member] | Using Significant Unobservable Inputs (Level 3) [Member]	'	'
Financial assets and liabilities that are measured at fair value on recurring basis	'	'
Assets, fair value	'	0
Municipal bonds [Member]	'	'
Financial assets and liabilities that are measured at fair value on recurring basis	'	'
Assets, fair value	805,704	200,070
Municipal bonds [Member] | Using Quoted Prices in Active Markets for Identical Assets (Level 1) [Member]	'	'
Financial assets and liabilities that are measured at fair value on recurring basis	'	'
Assets, fair value	0	0
Municipal bonds [Member] | Using Significant Other Unobservable Inputs (Level 2) [Member]	'	'
Financial assets and liabilities that are measured at fair value on recurring basis	'	'
Assets, fair value	805,704	200,070
Municipal bonds [Member] | Using Significant Unobservable Inputs (Level 3) [Member]	'	'
Financial assets and liabilities that are measured at fair value on recurring basis	'	'
Assets, fair value	0	0
Investment in affiliated entity [Member]	'	'
Financial assets and liabilities that are measured at fair value on recurring basis	'	'
Assets, fair value	9,664,587	10,703,332
Investment in affiliated entity [Member] | Using Quoted Prices in Active Markets for Identical Assets (Level 1) [Member]	'	'
Financial assets and liabilities that are measured at fair value on recurring basis	'	'
Assets, fair value	9,664,587	10,703,332
Investment in affiliated entity [Member] | Using Significant Other Unobservable Inputs (Level 2) [Member]	'	'
Financial assets and liabilities that are measured at fair value on recurring basis	'	'
Assets, fair value	0	0
Investment in affiliated entity [Member] | Using Significant Unobservable Inputs (Level 3) [Member]	'	'
Financial assets and liabilities that are measured at fair value on recurring basis	'	'
Assets, fair value	0	0
Common stock warrants [Member]	'	'
Financial assets and liabilities that are measured at fair value on recurring basis	'	'
Assets, fair value	717,500	267,200
Liabilities, fair value	19,540,583	2,859,899
Common stock warrants [Member] | Using Quoted Prices in Active Markets for Identical Assets (Level 1) [Member]	'	'
Financial assets and liabilities that are measured at fair value on recurring basis	'	'
Assets, fair value	0	0
Liabilities, fair value	0	0
Common stock warrants [Member] | Using Significant Other Unobservable Inputs (Level 2) [Member]	'	'
Financial assets and liabilities that are measured at fair value on recurring basis	'	'
Assets, fair value	0	0
Liabilities, fair value	0	0
Common stock warrants [Member] | Using Significant Unobservable Inputs (Level 3) [Member]	'	'
Financial assets and liabilities that are measured at fair value on recurring basis	'	'
Assets, fair value	717,500	267,200
Liabilities, fair value	$19,540,583	$2,859,899

Fair_Value_Measurements_Detail1

Fair Value Measurements (Details 1) (USD $)	12 Months Ended
	Dec. 31, 2013
Assumptions used to estimate the fair values of the common stock warrants	'
Dividend yield	$0
Minimum [Member]	'
Assumptions used to estimate the fair values of the common stock warrants	'
Risk-free interest rate	0.13%
Expected volatility	90.00%
Expected life in years	'6 months
Maximum [Member]	'
Assumptions used to estimate the fair values of the common stock warrants	'
Risk-free interest rate	1.75%
Expected volatility	112.00%
Expected life in years	'4 years 8 months 12 days
OncoSec common stock warrants [Member]	'
Assumptions used to estimate the fair values of the common stock warrants	'
Risk-free interest rate	0.78%
Expected volatility	85.00%
Dividend yield	$0
OncoSec common stock warrants [Member] | Minimum [Member]	'
Assumptions used to estimate the fair values of the common stock warrants	'
Expected life in years	'2 years 9 months
OncoSec common stock warrants [Member] | Maximum [Member]	'
Assumptions used to estimate the fair values of the common stock warrants	'
Expected life in years	'3 years 3 months

Fair_Value_Measurements_Detail2

Fair Value Measurements (Details 2) (Using Significant Unobservable Inputs (Level 3) [Member], USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Using Significant Unobservable Inputs (Level 3) [Member]	'	'
Change in fair value of the financial assets	'	'
Balance at beginning of year	$267,200	$100,000
Common stock warrant recorded at fair value upon acquisition	0	501,000
Increase (Decrease) in fair value included in change in fair value of common stock warrants	450,300	-333,800
Balance at end of year	$717,500	$267,200

Fair_Value_Measurements_Detail3

Fair Value Measurements (Details 3) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Changes in fair value of the financial liabilities	'	'	'
Increase (Decrease) in fair value included in change in fair value of common stock warrants	$46,082,969	($2,316,420)	($8,827,658)
Change in Classification of Warrants from Liability to Equity Due to Exercise	-35,370,529	'	'
Using Significant Unobservable Inputs (Level 3) [Member]	'	'	'
Changes in fair value of the financial liabilities	'	'	'
Balance at beginning of year	2,859,899	5,176,319	370,926
Increase (Decrease) in fair value included in change in fair value of common stock warrants	46,082,969	-2,316,420	-8,827,658
Change in Classification of Warrants from Liability to Equity Due to Exercise	-35,370,529	0	0
Balance at end of year	19,540,583	2,859,899	5,176,319
Warrant Issued in January 2011 [Member] | Warrants Issued [Member] | Using Significant Unobservable Inputs (Level 3) [Member]	'	'	'
Changes in fair value of the financial liabilities	'	'	'
Record fair value of warrants issued	0	0	11,727,372
Warrant Issued in December 2011 [Member] | Warrants Issued [Member] | Using Significant Unobservable Inputs (Level 3) [Member]	'	'	'
Changes in fair value of the financial liabilities	'	'	'
Record fair value of warrants issued	0	0	1,905,679
Warrant Issued in March 2013 [Member] | Warrants Issued [Member] | Using Significant Unobservable Inputs (Level 3) [Member]	'	'	'
Changes in fair value of the financial liabilities	'	'	'
Record fair value of warrants issued	$5,968,244	$0	$0

Fair_Value_Measurements_Detail4

Fair Value Measurements (Details Textual) (USD $)

12 Months Ended

12 Months Ended

1 Months Ended

12 Months Ended

1 Months Ended

12 Months Ended

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Sep. 30, 2012

Dec. 31, 2013

Mar. 31, 2013

Mar. 31, 2012

Dec. 31, 2013

Mar. 31, 2013

First warrant [Member]

First warrant [Member]

Using Quoted Prices in Active Markets for Identical Assets (Level 1) [Member]

Using Quoted Prices in Active Markets for Identical Assets (Level 1) [Member]

Using Significant Unobservable Inputs (Level 3) [Member]

Using Significant Unobservable Inputs (Level 3) [Member]

Using Significant Unobservable Inputs (Level 3) [Member]

Using Significant Unobservable Inputs (Level 3) [Member]

Using Significant Unobservable Inputs (Level 3) [Member]

Using Significant Unobservable Inputs (Level 3) [Member]

Using Significant Unobservable Inputs (Level 3) [Member]

Using Significant Unobservable Inputs (Level 3) [Member]

Using Significant Unobservable Inputs (Level 3) [Member]

warrant

First warrant [Member]

First warrant [Member]

First warrant [Member]

Second warrant [Member]

Second warrant [Member]

Second warrant [Member]

Marketable Securities and Fair Value Measurements (Textual) [Abstract]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Number of shares held in an affiliated entity

'

'

'

'

'

8,220,775

8,220,775

'

'

'

'

'

'

'

'

'

Number of warrants received to purchase shares of common stock

'

'

'

'

'

'

'

2

'

'

'

'

'

'

'

'

Common stock purchase warrant

'

'

'

'

'

'

'

21,164,997

'

'

'

'

1,000,000

'

'

3,000,000

Term of the warrants in years

'

'

'

'

'

'

'

'

'

'

'

'5 years

'

'

'5 years

'

Exercise price of a five-year warrant

'

'

'

'

'

'

'

'

'

'

$1.20

'

'

$1

'

'

Long-term asset associated with warrants

$718,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Gain on sale of asset

501,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Change in the fair value

46,082,969

-2,316,420

-8,827,658

450,000

-334,000

'

'

46,082,969

-2,316,420

-8,827,658

'

'

'

'

'

'

Common stock warrants

$19,540,583

$2,859,899

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Major_Customers_and_Concentrat2

Major Customers and Concentration of Credit Risk (Details) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Concentration Risk [Line Items]	'	'	'
Revenue	$13,467,346	$4,118,652	$9,795,257
Revenue [Member] | Customer Concentration Risk [Member]	'	'	'
Concentration Risk [Line Items]	'	'	'
Concentration risk, percentage	100.00%	100.00%	100.00%
Roche [Member]	'	'	'
Concentration Risk [Line Items]	'	'	'
Revenue	9,181,759	0	0
Accounts receivable	2,600,000	'	'
Roche [Member] | Revenue [Member] | Customer Concentration Risk [Member]	'	'	'
Concentration Risk [Line Items]	'	'	'
Concentration risk, percentage	68.00%	0.00%	0.00%
Roche [Member] | Accounts Receivable [Member] | Customer Concentration Risk [Member]	'	'	'
Concentration Risk [Line Items]	'	'	'
Concentration risk, percentage	79.00%	'	'
NIAID [Member]	'	'	'
Concentration Risk [Line Items]	'	'	'
Revenue	2,090,939	2,831,115	7,801,976
Accounts receivable	382,000	612,000	'
NIAID [Member] | Revenue [Member] | Customer Concentration Risk [Member]	'	'	'
Concentration Risk [Line Items]	'	'	'
Concentration risk, percentage	16.00%	69.00%	80.00%
NIAID [Member] | Accounts Receivable [Member] | Customer Concentration Risk [Member]	'	'	'
Concentration Risk [Line Items]	'	'	'
Concentration risk, percentage	12.00%	71.00%	'
VGX Int'l [Member]	'	'	'
Concentration Risk [Line Items]	'	'	'
Revenue	425,000	577,467	411,459
VGX Int'l [Member] | Revenue [Member] | Customer Concentration Risk [Member]	'	'	'
Concentration Risk [Line Items]	'	'	'
Concentration risk, percentage	3.00%	14.00%	4.00%
University of Pennsylvania [Member]	'	'	'
Concentration Risk [Line Items]	'	'	'
Accounts receivable	'	95,000	'
University of Pennsylvania [Member] | Accounts Receivable [Member] | Customer Concentration Risk [Member]	'	'	'
Concentration Risk [Line Items]	'	'	'
Concentration risk, percentage	'	11.00%	'
All Other Customers [Member]	'	'	'
Concentration Risk [Line Items]	'	'	'
Revenue	$1,769,648	$710,070	$1,581,822
All Other Customers [Member] | Revenue [Member] | Customer Concentration Risk [Member]	'	'	'
Concentration Risk [Line Items]	'	'	'
Concentration risk, percentage	13.00%	17.00%	16.00%

Fixed_Assets_Details

Fixed Assets (Details) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Property, Plant and Equipment [Line Items]	'	'	'
Cost	$4,801,973	$2,480,723	'
Accumulated Depreciation and Amortization	-1,915,428	-2,117,702	'
Net Book Value	2,886,545	363,021	'
Depreciation	328,752	173,750	142,197
Machinery, equipment and office furniture [Member]	'	'	'
Property, Plant and Equipment [Line Items]	'	'	'
Cost	2,381,033	2,014,588	'
Accumulated Depreciation and Amortization	-1,807,706	-1,731,660	'
Net Book Value	573,327	282,928	'
Leasehold improvements [Member]	'	'	'
Property, Plant and Equipment [Line Items]	'	'	'
Cost	2,420,940	466,135	'
Accumulated Depreciation and Amortization	-107,722	-386,042	'
Net Book Value	$2,313,218	$80,093	'

Goodwill_and_Intangible_Assets2

Goodwill and Intangible Assets (Details) (USD $)

Dec. 31, 2013

Dec. 31, 2012

Jan. 31, 2005

Jun. 30, 2009

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Inovio AS [Member]

VGX [Member]

Minimum [Member]

Maximum [Member]

Patents [Member]

Patents [Member]

Patents [Member]

Patents [Member]

Licenses [Member]

Licenses [Member]

Licenses [Member]

Licenses [Member]

CELLECTRA [Member]

CELLECTRA [Member]

CELLECTRA [Member]

CELLECTRA [Member]

GHRH [Member]

GHRH [Member]

Other [Member]

Other [Member]

Minimum [Member]

Maximum [Member]

Minimum [Member]

Maximum [Member]

Minimum [Member]

Maximum [Member]

Schedule of intangible assets by major asset class

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Useful Life (Yrs)

'

'

'

'

'5 years

'18 years

'

'

'8 years

'17 years

'

'

'8 years

'17 years

'

'

'5 years

[1]

'11 years

[1]

'11 years

[1]

'

'18 years

[2]

'

Non-Amortizing:

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Goodwill, Gross

$10,113,371

[3]

$10,113,371

[3]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Goodwill, Net Book Value

10,113,371

[3]

10,113,371

[3]

3,900,000

6,200,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Amortizing:

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Intangible assets, Gross

19,617,873

19,617,873

'

'

'

'

5,802,528

5,802,528

'

'

1,323,761

1,323,761

'

'

8,106,270

[1]

8,106,270

[1]

'

'

335,314

[1]

335,314

[1]

4,050,000

[2]

4,050,000

[2]

Intangible assets, Accumulated Amortization

-13,899,095

-12,128,558

'

'

'

'

-5,128,227

-4,852,673

'

'

-1,075,617

-1,046,870

'

'

-5,543,786

[1]

-4,334,234

[1]

'

'

-145,215

[1]

-113,531

[1]

-2,006,250

[2]

-1,781,250

[2]

Intangible assets, Net Book Value

5,718,778

7,489,315

'

'

'

'

674,301

949,855

'

'

248,144

276,891

'

'

2,562,484

[1]

3,772,036

[1]

'

'

190,099

[1]

221,783

[1]

2,043,750

[2]

2,268,750

[2]

Total goodwill and intangible assets, Gross

29,731,244

29,731,244

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Total goodwill and intangible assets, Net Book Value

$15,832,149

$17,602,686

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

[1]

CELLECTRAB. and GHRH are developed technologies which were recorded from the acquisition of VGX.

[2]

Other intangible assets represent the fair value of acquired intellectual property from the Inovio AS acquisition.

[3]

Goodwill was recorded from the Inovio AS acquisition in January 2005 and from the acquisition of VGX in June 2009 for $3.9 million and $6.2 million, respectively.

Goodwill_and_Intangible_Assets3

Goodwill and Intangible Assets (Details 1) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Goodwill and Intangible Assets (Textual) [Abstract]	'	'	'
Aggregate amortization expense on intangible assets	$1,770,537	$1,821,170	$1,869,517
Estimated aggregate amortization expense for 2014	943,000	'	'
Estimated aggregate amortization expense for 2015	870,000	'	'
Estimated aggregate amortization expense for 2016	816,000	'	'
Estimated aggregate amortization expense for 2017	775,000	'	'
Estimated aggregate amortization expense for 2018	773,000	'	'
Estimated aggregate amortization expense thereafter	1,542,000	'	'
Intangible assets, Net Book Value	$5,718,778	$7,489,315	'

Goodwill_and_Intangible_Assets4

Goodwill and Intangible Assets (Details Textual) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Goodwill and Intangible Assets Disclosure [Abstract]	'	'	'
Goodwill, impairment loss	$0	$0	$0

Accounts_Payable_and_Accrued_E2

Accounts Payable and Accrued Expenses (Details) (USD $)	Dec. 31, 2013	Dec. 31, 2012
Payables and Accruals [Abstract]	'	'
Trade accounts payable	$1,865,723	$852,573
Accrued compensation	2,586,806	1,560,704
Other accrued expenses	991,979	768,297
Accounts payable and accrued liabilities	$5,444,508	$3,181,574

Stockholders_Equity_Details

Stockholders' Equity (Details) (USD $)	Dec. 31, 2013	Dec. 31, 2012
Summary of common and preferred stock authorized, issued and outstanding	'	'
Preferred Stock, par value (Dollars per share)	$0.00	$0.00
Preferred Stock, Shares Authorized	10,000,000	10,000,000
Preferred Stock, Shares Issued	26	26
Preferred Stock, Shares Outstanding	26	26
Series A Preferred Stock [Member]	'	'
Summary of common and preferred stock authorized, issued and outstanding	'	'
Preferred Stock, par value (Dollars per share)	$0.00	$0.00
Preferred Stock, Shares Authorized	1,000	1,000
Preferred Stock, Shares Issued	817	817
Preferred Stock, Shares Outstanding	0	0
Series B Preferred Stock [Member]	'	'
Summary of common and preferred stock authorized, issued and outstanding	'	'
Preferred Stock, par value (Dollars per share)	$0.00	$0.00
Preferred Stock, Shares Authorized	1,000	1,000
Preferred Stock, Shares Issued	750	750
Preferred Stock, Shares Outstanding	0	0
Series C Preferred Stock [Member]	'	'
Summary of common and preferred stock authorized, issued and outstanding	'	'
Preferred Stock, par value (Dollars per share)	$0.00	$0.00
Preferred Stock, Shares Authorized	1,091	1,091
Preferred Stock, Shares Issued	1,091	1,091
Preferred Stock, Shares Outstanding	26	26
Series D Preferred Stock [Member]	'	'
Summary of common and preferred stock authorized, issued and outstanding	'	'
Preferred Stock, par value (Dollars per share)	$0.00	$0.00
Preferred Stock, Shares Authorized	1,966,292	1,966,292
Preferred Stock, Shares Issued	1,966,292	1,966,292
Preferred Stock, Shares Outstanding	0	0

Stockholders_Equity_Details_1

Stockholders' Equity (Details 1) (USD $)

Dec. 31, 2013

Dec. 31, 2012

Jan. 31, 2011

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

March 2013 financing [Member]

March 2013 financing [Member]

December 2011 financing [Member]

December 2011 financing [Member]

January 2011 financing [Member]

January 2011 financing [Member]

July 2009 financing [Member]

July 2009 financing [Member]

Warrants assumed in June 2009 Merger [Member]

Warrants assumed in June 2009 Merger [Member]

Minimum [Member]

Minimum [Member]

Maximum [Member]

Maximum [Member]

Warrants assumed in June 2009 Merger [Member]

Warrants assumed in June 2009 Merger [Member]

Warrants assumed in June 2009 Merger [Member]

Warrants assumed in June 2009 Merger [Member]

Summary of warrants outstanding

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Exercise Price

'

'

1.4

0.79

0.79

0.65

0.65

1.4

1.4

3.38

3.38

'

'

1.02

1.02

1.28

1.28

Expiration Date

'

'

'

12-Sep-18

'

6-Dec-16

'

27-Jan-16

'

1-Jul-14

'

'

'

1-Aug-15

'

28-Apr-16

'

Number of Warrants

14,059,260

21,593,844

'

3,022,725

0

0

5,774,784

6,695,000

10,565,200

333,333

333,333

4,008,202

4,920,527

'

'

'

'

Common Stock Warrant Liability

$19,540,583

$2,859,899

'

$7,859,085

$0

$0

$2,078,921

$11,381,498

$779,711

$300,000

$1,267

$0

$0

'

'

'

'

Stockholders_Equity_Details_2

Stockholders' Equity (Details 2) (USD $)	12 Months Ended
	Dec. 31, 2013
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'
Options Outstanding	16,538,118
Weighted-Average Remaining Contractual Life	'5 years 6 months 12 days
Weighted Average Exercise Price	$1.21
Options Exercisable	12,690,114
Weighted-Average Exercise Price	$1.38
$0.00 b $1.00 [Member]	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'
Exercise price, lower range limit	$0
Exercise price, upper range limit	$1
Options Outstanding	5,888,591
Weighted-Average Remaining Contractual Life	'8 years 1 month 30 days
Weighted Average Exercise Price	$0.56
Options Exercisable	2,561,431
Weighted-Average Exercise Price	$0.57
$1.01 b $2.00 [Member]	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'
Exercise price, lower range limit	$1.01
Exercise price, upper range limit	$2
Options Outstanding	9,363,064
Weighted-Average Remaining Contractual Life	'4 years 1 month 21 days
Weighted Average Exercise Price	$1.32
Options Exercisable	8,903,626
Weighted-Average Exercise Price	$1.32
$2.01 b $4.00 [Member]	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'
Exercise price, lower range limit	$2.01
Exercise price, upper range limit	$4
Options Outstanding	1,047,713
Weighted-Average Remaining Contractual Life	'3 years 1 month 0 days
Weighted Average Exercise Price	$3.02
Options Exercisable	986,307
Weighted-Average Exercise Price	$3.06
$4.01 b $6.00 [Member]	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'
Exercise price, lower range limit	$4.01
Exercise price, upper range limit	$6
Options Outstanding	188,750
Weighted-Average Remaining Contractual Life	'0 years 3 months 27 days
Weighted Average Exercise Price	$4.86
Options Exercisable	188,750
Weighted-Average Exercise Price	$4.86
$6.01 b $6.12 [Member]	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'
Exercise price, lower range limit	$6.01
Exercise price, upper range limit	$6.12
Options Outstanding	50,000
Weighted-Average Remaining Contractual Life	'0 years 2 months 23 days
Weighted Average Exercise Price	$6.12
Options Exercisable	50,000
Weighted-Average Exercise Price	$6.12

Stockholders_Equity_Details_3

Stockholders' Equity (Details 3) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2009
Number of Shares	'	'	'	'
Beginning Balance	16,257,444	14,302,803	'	12,649,968
Granted	2,913,625	2,733,750	2,068,750	'
Exercised	-1,925,214	0	-68,309	'
Cancelled	-707,737	-779,109	-347,606	'
Ending Balance	16,538,118	16,257,444	14,302,803	12,649,968
Weighted-Average Exercise Price	'	'	'	'
Beginning Balance	$1.28	$1.42	'	$1.49
Granted	$0.61	$0.58	$1.10	'
Exercised	$0.81	$0	$0.23	'
Cancelled	$1.30	$1.55	$2.25	'
Ending Balance	$1.21	$1.28	$1.42	$1.49

Stockholders_Equity_Details_Te

Stockholders' Equity (Details Textual) (USD $)

12 Months Ended

12 Months Ended

0 Months Ended

12 Months Ended

1 Months Ended

12 Months Ended

1 Months Ended

12 Months Ended

1 Months Ended

12 Months Ended

1 Months Ended

12 Months Ended

12 Months Ended

12 Months Ended

12 Months Ended

12 Months Ended

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

31-May-13

Apr. 30, 2013

Jan. 31, 2011

Dec. 31, 2009

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

14-May-10

Dec. 31, 2013

Dec. 31, 2013

Aug. 31, 2012

Dec. 31, 2013

Jun. 30, 2012

Dec. 31, 2013

Dec. 31, 2012

Mar. 31, 2013

Dec. 31, 2011

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2012

Jan. 31, 2011

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Employee [Member]

Employee [Member]

Employee [Member]

Research and Development Expense [Member]

Research and Development Expense [Member]

Research and Development Expense [Member]

General and Administrative Expense [Member]

General and Administrative Expense [Member]

General and Administrative Expense [Member]

Non Employee [Member]

Non Employee [Member]

Non Employee [Member]

Stock and Cash Based Incentive Plan [Member]

Stock and Cash Based Incentive Plan [Member]

Amended 2000 Stock Option Plan [Member]

Common Stock Warrants [Member]

Common Stock Warrants [Member]

Sales Agreement [Member]

Sales Agreement [Member]

Sales Agreement [Member]

Underwritten public offering [Member]

Underwritten public offering [Member]

Underwritten public offering [Member]

Underwritten public offering [Member]

Overallotment option [Member]

Investor purchase agreements [Member]

Investor purchase agreements [Member]

Investor purchase agreements [Member]

VGX Equity Compensation Plan [Member]

Minimum [Member]

Series C Preferred Stock [Member]

Series C Preferred Stock [Member]

March 2013 financing [Member]

March 2013 financing [Member]

December Two Thousand Eleven Financing [Member]

December Two Thousand Eleven Financing [Member]

January Two Thousand Eleven Financing [Member]

January Two Thousand Eleven Financing [Member]

Preferred Stock [Abstract]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Preferred stock, redemption price per share

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$10,000

'

'

'

'

'

'

'

Preferred stock, par value (Dollars per share)

$0.00

$0.00

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$0.00

$0.00

'

'

'

'

'

'

Notice period for mandatory conversion of preferred stock

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'30 days

'

'

'

'

'

'

'

Average daily trading volume triggering mandatory conversion

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

25,000

'

'

'

'

'

'

'

'

Convertible preferred stock, shares issued upon conversion

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

38,233

'

'

'

'

'

'

'

Convertible preferred stock, shares issued upon conversion, conversion price per share

$6.80

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Daily market price triggering mandatory conversion

$18

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stockholders' Equity (Textual) [Abstract]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock, shares authorized

600,000,000

300,000,000

'

600,000,000

300,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock, capital shares reserved for future issuance

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

27,377,266

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Class of warrant or right, number of securities called by warrants or rights

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

13,688,633

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Class of warrant or right, number of securities called by each warrant or right

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0.5

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Class of warrant or right, securities called by warrants or rights, price per share

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$0.79

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Potential proceeds from issue of common stock

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$14,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Warrants, fair value disclosure

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

6,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Increase (decrease) in fair value of warrants

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

25,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock issued during period, shares, warrants exercised

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

10,665,908

'

5,774,784

'

3,870,200

'

Transaction costs associated with issuance of warrants

315,970

0

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Potential sales proceeds

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

25,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Rate of commission or discount rate to placement agent

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

3.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Shares of common stock sold under sales agreement

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

15,700,668

9,344,611

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Weighted average price per share on sale of common stock

$1.24

$0.59

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Net proceeds from the transaction

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

18,900,000

5,300,000

'

3,700,000

'

'

'

23,000,000

'

'

'

'

'

'

8,500,000

'

3,800,000

'

5,400,000

'

Common stock shares issued

210,304,821

144,313,005

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

7,699,712

962,465

21,130,400

'

'

'

'

'

'

'

'

'

'

'

'

Warrants to purchase number of shares of common stock

14,059,260

21,593,844

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

5,774,784

'

10,565,200

'

'

'

'

'

'

3,022,725

0

0

5,774,784

6,695,000

10,565,200

Purchase price per unit of common stock and warrant

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0.55

0.5195

'

'

'

1.15

'

'

'

'

'

'

'

'

'

'

'

'

Ratio to determine the number of warrants received per one share of common stock sold

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0.75

'

'

'

0.5

'

'

'

'

'

'

'

'

'

'

'

'

Term of the warrants in years

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'5 years 6 months

'

'

'5 years

'

'5 years

'

'

'

'

'

'

'

'

'

'

'

'

Exercise Price

'

'

'

'

'

1.4

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0.65

'

'

'

'

'

'

'

'

0.79

0.79

0.65

0.65

1.4

1.4

Closing bid price of warrants, minimum

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$1.30

'

'

'

$2.80

'

'

'

'

'

'

'

'

'

'

'

'

Trading date of warrants in days

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'20 days

'

'

'

'20 days

'

'

'

'

'

'

'

'

'

'

'

'

Change in fair value of warrants

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

-4,900,000

115,000

'

'

-15,800,000

2,400,000

'

'

'

'

'

'

'

'

'

'

Aggregate purchase price under securities purchase agreement

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

24,300,000

'

'

'

'

'

'

'

'

'

'

'

'

First exercisable date from the date of issuance in days

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'180 days

'

'

'

'

'

'

'

'

'

'

'

'

Class of warrant or right, number of warrants exercised

3,870,200

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Warrants expired to purchase number of shares of common stock

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

150,000

58,220

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Increased number of securities available for future issuance

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Number of potential shares authorized for issuance under a share-based compensation plan

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2,055,331

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Reserved number of shares under the Incentive Plan

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

11,915,993

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Increased aggregate number of shares available for grants under the Incentive Plan

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1,197,306

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Number of shares of vested restricted stock outstanding under the plan

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

240,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Number of common stock outstanding under the Incentive Plan

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

9,163,063

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Vesting period of Incentive Plan

'3 years

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Contractual year term of Incentive Plan

'10 years

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Number of options outstanding to purchase common stock

16,538,118

16,257,444

14,302,803

'

'

'

12,649,968

'

'

'

'

'

'

'

'

'

4,794,496

'

'

'

'

1,091,750

'

'

'

'

'

'

'

'

'

'

'

'

'

6,283,305

'

'

'

'

'

'

'

'

'

Share-based Compensation

1,868,345

1,345,613

1,654,823

'

'

'

'

1,200,000

1,200,000

1,600,000

550,000

555,000

472,000

605,000

638,000

1,100,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Employee service share-based compensation, nonvested awards, total compensation cost not yet recognized

956,000

944,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Employee service share-based compensation, nonvested awards, total compensation cost not yet recognized, period for recognition

'1 year 10 months 0 days

'1 year 10 months 24 days

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Allocated Share-based Compensation Expense

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

714,000

153,000

33,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Aggregate intrinsic value of options outstanding

28,700,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Aggregate intrinsic value for options exercisable

20,100,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Options exercisable, remaining contractual term

'4 years 8 months 12 days

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Number of options expected to vest

3,540,163

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Options, expirations in period, weighted average exercise price

$1.33

$1.83

$2.08

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Options, expirations in period

496,012

207,498

100,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Options, grants in period, weighted average grant date fair value

$0.44

$0.47

$0.90

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Proceeds from stock options exercised

1,600,000

0

16,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Options, exercises in period, aggregate intrinsic value

$2,500,000

$0

$65,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Commitments_Details

Commitments (Details) (USD $)	Dec. 31, 2013
In Thousands, unless otherwise specified
Commitments and Contingencies Disclosure [Abstract]	'
2014	$233
2015	677
2016	817
2017	739
2018	668
Thereafter	4,620
Total	$7,754

Commitments_Details_Textual

Commitments (Details Textual) (USD $)	12 Months Ended				1 Months Ended		1 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2013	Apr. 30, 2013	Dec. 31, 2013	Apr. 30, 2013	Apr. 30, 2013
				Pennsylvania Office [Member]	San Diego Office [Member]	San Diego Office [Member]	Minimum [Member]	Maximum [Member]
				sqft	sqft		San Diego Office [Member]	San Diego Office [Member]
Operating Leased Assets [Line Items]	'	'	'	'	'	'	'	'
Area of leased office space	'	'	'	8,761	'	'	'	'
Lease renewal option, term	'	'	'	'3 years	'	'	'	'
Area of additional leased office space	'	'	'	'	26,500	'	'	'
Initial lease term	'	'	'	'	'10 years	'	'	'
Monthly payments under the lease	'	'	'	'	'	'	$0	$82,945
Security deposit	'	'	'	'	64,000	'	'	'
Leasehold improvements	'	'	'	'	'	2,300,000	'	'
Rent expense, net	$906,000	$444,000	$430,000	'	'	'	'	'

Investment_in_Affiliated_Entit1

Investment in Affiliated Entity (Details) (VGX International [Member])	Dec. 31, 2013	Dec. 31, 2012
VGX International [Member]	'	'
Related Party Transaction [Line Items]	'	'
Equity Method Investment, Ownership Percentage	14.70%	16.10%

Income_Taxes_Details

Income Taxes (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Current:	'	'	'
Federal	$0	$0	$0
State	-1	7	1
Current Income Tax Expense (Benefit)	-1	7	1
Deferred:	'	'	'
Federal	15	20	19
State	17	3	7
Deferred Income Tax Expense (Benefit)	32	23	26
Income Tax Expense (Benefit)	$31	$30	$27

Income_Taxes_Details_1

Income Taxes (Details 1) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Income Tax Disclosure [Abstract]	'	'	'
Statutory tax rate	35.00%	35.00%	35.00%
Income Tax Expense (Benefit), Continuing Operations, Income Tax Reconciliation [Abstract]	'	'	'
Income (benefit) taxes at statutory rates	($23,118)	($6,894)	($5,352)
State income tax, net of federal benefit	-1,651	-1,234	-1,378
Change in valuation allowance	8,819	7,415	7,679
IRC Section 382/383 limitation	675	18	918
Fair value warrant	16,129	-811	-3,090
Stock compensation	279	603	-147
Change in state tax rate	-623	438	125
Other	-479	495	1,272
Income Tax Expense (Benefit)	$31	$30	$27

Income_Taxes_Details_2

Income Taxes (Details 2) (USD $)	Dec. 31, 2013	Dec. 31, 2012
Deferred tax assets:	'	'
Capitalized research expense	$2,782,000	$3,191,000
Net operating loss carryforwards	48,846,000	43,233,000
Research and development and other tax credits	1,877,000	1,134,000
Other	8,641,000	6,569,000
Deferred Tax Assets, Gross	62,146,000	54,127,000
Valuation allowance	-61,061,000	-52,185,000
Total deferred tax assets	1,085,000	1,942,000
Deferred tax liabilities:	'	'
Acquired intangibles	-1,096,000	-1,532,000
Investment in affiliated entity	-123,000	-511,000
Net deferred tax liabilities	($134,000)	($101,000)

Income_Taxes_Details_3

Income Taxes (Details 3) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]	'	'	'
Balance at beginning of the year	$1,896	$1,829	$629
Increases related to current year tax positions	305	72	158
Increases (Decreases) related to prior year tax positions	215	-5	1,042
Balance at end of the year	$2,416	$1,896	$1,829

Income_Taxes_Details_Textual

Income Taxes (Details Textual) (USD $)	Dec. 31, 2013
In Millions, unless otherwise specified
Operating Loss Carryforwards [Line Items]	'
Tax benefits expired	$28.30
Unrecognized tax benefits that would impact effective tax rate	2
Federal [Member]	'
Operating Loss Carryforwards [Line Items]	'
Net operating loss carryforwards that will expire due to IRC Section 382 limitations	122.4
California [Member]	'
Operating Loss Carryforwards [Line Items]	'
Net operating loss carryforwards that will expire due to IRC Section 382 limitations	38.9
Pennsylvania [Member]	'
Operating Loss Carryforwards [Line Items]	'
Net operating loss carryforwards that will expire due to IRC Section 382 limitations	75.6
Research Tax Credit Carryforward [Member] | Federal [Member]	'
Operating Loss Carryforwards [Line Items]	'
Tax credit carryforward amount	2
Research Tax Credit Carryforward [Member] | State [Member]	'
Operating Loss Carryforwards [Line Items]	'
Tax credit carryforward amount	$2.10

401k_Plan_Details

401(k) Plan (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Compensation and Retirement Disclosure [Abstract]	'	'	'
Employer matching contribution, percent	50.00%	'	'
Maximum annual contribution per employee, percent	6.00%	'	'
Company's contribution to 401(k) plan	$196	$170	$134

Related_Party_Transactions_Det

Related Party Transactions (Details) (USD $)	Dec. 31, 2013	Dec. 31, 2012	Jul. 31, 2011	Mar. 24, 2010	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2013	Sep. 28, 2011	Mar. 24, 2012
			VGX Int'l [Member]	VGX Int'l [Member]	VGX Int'l [Member]	VGX Int'l [Member]	VGX Int'l [Member]	OncoSec [Member]	OncoSec [Member]	OncoSec [Member]
									First warrant [Member]	Second warrant [Member]
Related-Party Transactions (Textual) [Abstract]	'	'	'	'	'	'	'	'	'	'
Additional shares purchased in VGX Int'l	'	'	145,000	'	'	'	'	'	'	'
Sale price per share	'	'	$0.71	'	'	'	'	'	'	'
Percentage of ownership	'	'	'	'	14.70%	16.10%	'	'	'	'
Payment received for license granted	'	'	'	$3,000,000	'	'	'	'	'	'
Deferred revenue from affiliated entity	'	'	'	3,000,000	'	'	'	'	'	'
Period over which deferred revenue from affiliated entity will be recognized in years	'	'	'	'8 years	'	'	'	'	'	'
Revenue from related parties	'	'	'	'	425,000	577,000	411,000	'	'	'
Operating expenses related to affiliated entity	'	'	'	'	2,300,000	871,000	5,300,000	'	'	'
Accounts receivable from related parties	'	'	'	'	0	36,000	'	'	'	'
Long-term other assets	402,075	134,193	'	'	231,000	'	'	'	'	'
Payment made to affiliated entity	'	'	'	'	300,000	'	'	'	'	'
Payments received from affiliate	'	'	'	'	'	'	'	$3,000,000	'	'
Common stock purchase warrant	'	'	'	'	'	'	'	'	1,000,000	3,000,000
Term of the warrants in years	'	'	'	'	'	'	'	'	'5 years	'5 years
Exercise price of a five-year warrant	'	'	'	'	'	'	'	'	$1.20	$1

Quarterly_Financial_Informatio2

Quarterly Financial Information (Unaudited) (Details) (USD $)	3 Months Ended								12 Months Ended
	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2012	Sep. 30, 2012	Jun. 30, 2012	Mar. 31, 2012	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Quarterly Financial Information Disclosure [Abstract]	'	'	'	'	'	'	'	'	'	'	'
Revenue under collaborative research and development arrangements	$822,217	$8,388,760	$14,311	$14,259	$14,296	$22,495	$20,907	$24,838	$9,239,547	$82,536	$156,397
Revenue under collaborative research and development arrangements with affiliated entity	106,250	106,250	106,250	106,250	142,483	222,484	106,250	106,250	425,000	577,467	411,459
Grants and miscellaneous revenue	811,199	991,835	665,049	1,334,716	977,974	609,717	308,925	1,562,033	3,802,799	3,458,649	9,227,401
Total revenues	1,739,666	9,486,845	785,610	1,455,225	1,134,753	854,696	436,082	1,693,121	13,467,346	4,118,652	9,795,257
Research and development	6,404,005	5,438,405	4,411,082	5,115,112	4,442,841	4,972,319	4,527,086	4,042,579	21,368,604	17,984,825	20,032,001
General and administrative	4,339,539	3,282,796	3,046,586	2,974,153	2,919,000	2,674,362	2,696,909	2,488,088	13,643,074	10,778,359	11,988,796
Gain on sale of assets	-1,000,000	0	-1,000,000	0	0	-500,000	0	-651,000	-2,000,000	-1,151,000	-587,000
Total operating expenses	9,743,544	8,721,201	6,457,668	8,089,265	7,361,841	7,146,681	7,223,995	5,879,667	33,011,678	27,612,184	31,433,797
Loss from operations	-8,003,878	765,644	-5,672,058	-6,634,040	-6,227,088	-6,291,985	-6,787,913	-4,186,546	-19,544,332	-23,493,532	-21,638,540
Interest and other income, net	8,576	46,787	37,391	39,460	56,520	37,013	41,036	31,544	132,214	166,113	34,285
Change in fair value of common stock warrants	-6,052,965	-34,952,210	-3,199,878	-1,427,616	3,049,649	-1,113,638	3,594,782	-3,548,173	-45,632,669	1,982,620	8,690,658
(Loss) Gain from investment in affiliated entity	-1,419,536	3,248,926	-2,032,051	-836,084	2,449,615	736,121	-992,373	-561,544	-1,038,745	1,631,819	-2,390,498
Net loss	-15,467,803	-30,890,853	-10,866,596	-8,858,280	-671,304	-6,632,489	-4,144,468	-8,264,719	-66,083,532	-19,712,980	-15,304,095
Net loss attributable to non-controlling interest	13,473	13,443	14,008	14,160	12,553	10,413	11,289	9,770	55,084	44,025	51,150
Net loss attributable to Inovio Pharmaceuticals, Inc.	($15,454,330)	($30,877,410)	($10,852,588)	($8,844,120)	($658,751)	($6,622,076)	($4,133,179)	($8,254,949)	($66,028,448)	($19,668,955)	($15,252,945)
Net loss attributable to Inovio Pharmaceuticals, Inc. stockholders (In dollars per share)	($0.07)	($0.16)	($0.06)	($0.06)	$0	($0.05)	($0.03)	($0.06)	($0.36)	($0.14)	($0.12)
Weighted average number of common sharesbbasic and diluted (In shares)	208,509,676	191,956,155	179,954,816	156,155,532	140,704,889	135,389,308	134,968,394	134,968,394	184,351,090	136,509,247	126,239,336

Subsequent_Events_Details

Subsequent Events (Details) (USD $)

12 Months Ended

1 Months Ended

1 Months Ended

12 Months Ended

0 Months Ended

3 Months Ended

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Mar. 17, 2014

Mar. 07, 2014

Mar. 17, 2014

Mar. 17, 2014

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Mar. 04, 2014

Mar. 04, 2014

Sep. 30, 2014

Subsequent Event [Member]

Plymouth Meeting, Pennsylvania [Member]

Plymouth Meeting, Pennsylvania [Member]

Plymouth Meeting, Pennsylvania [Member]

Common Stock [Member]

Common Stock [Member]

Common Stock [Member]

Common Stock [Member]

Common Stock [Member]

Scenario, Forecast [Member]

Subsequent Event [Member]

Minimum [Member]

Maximum [Member]

Underwritten public offering [Member]

Underwritten Public Offering Overallotment Option [Member]

Plymouth Meeting, Pennsylvania [Member]

Subsequent Event [Member]

Subsequent Event [Member]

Subsequent Event [Member]

Subsequent Event [Member]

Subsequent Event [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock shares issued

'

'

'

'

'

'

'

15,700,668

9,344,611

1,028,905

21,810,900

2,844,900

'

Public offering price

'

'

'

'

'

'

'

'

'

'

$2.90

'

'

Proceeds from issuance of common stock and warrants, net of issuance costs

$32,883,705

$5,325,141

$27,994,601

'

'

'

'

'

'

'

$59,200,000

'

'

Initial lease term

'

'

'

'

'

'

'

'

'

'

'

'

'11 years 6 months

Monthly payments under the lease

'

'

'

'

'

0

58,000

'

'

'

'

'

'

Security deposit

'

'

'

'

49,000

'

'

'

'

'

'

'

'

Number of common stock from warrants and stock options exercised

'

'

'

7,619,039

'

'

'

'

'

'

'

'

'

Proceeds from warrants and stock options exercised

'

'

'

$10,200,000

'

'

'

'

'

'

'

'

'